Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 34
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Working definitions, subjective and objective assessments and experimental paradigms in a study exploring social withdrawal in schizophrenia and Alzheimer's disease

  • Van der Wee, Nic J.A.
  • Bilderbeck, Amy C.
  • Ayuso Mateos, José Luis
  • Saris, Ilya M.J.
  • Giltay, Erik J.
  • Penninx, Brenda W.J.H.
  • Arango López, Celso
  • Post, Anke
  • Porcelli, Stefano
  • Cabello Salmerón, María
Social withdrawal is one of the first and common signs of early social dysfunction in a number of important neuropsychiatric disorders, likely because of the enormous amount and complexity of brain processes required to initiate and maintain social relationships (Adolphs, 2009). The Psychiatric Ratings using Intermediate Stratified Markers (PRISM) project focusses on the shared and unique neurobiological basis of social withdrawal in schizophrenia, Alzheimer and depression. In this paper, we discuss the working definition of social withdrawal for this study and the selection of objective and subjective rating scales to assess social withdrawal chosen or adapted for this project. We also discuss the MRI and EEG paradigms selected to study the systems and neural circuitry thought to underlie social functioning and more particularly to be involved in social withdrawal in humans, such as the social perception and the social affiliation networks. A number of behavioral paradigms were selected to assess complementary aspects of social cognition. Also, a digital phenotyping method (a smartphone application) was chosen to obtain real-life data., This work was supported by the European Union Horizon 2020 Innovative Medicines Initiative 2 Joint Undertaking grant 115916 for the project ‘Psychiatric ratings using intermediate stratified markers’
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Digital behavioural signatures reveal trans-diagnostic clusters of Schizophrenia and Alzheimer's disease patients: trans-diagnostic clustering of digital biotypes

  • Kas, Martien J.H.
  • Jongs, Niels
  • Mennes, Maarten
  • Penninx, Brenda W.J.H.
  • Arango López, Celso
  • van der Wee, Nic
  • Winter-van Rossum, Inge
  • Ayuso Mateos, José Luis
  • Bilderbeck, Amy C.
  • l'Hostis, Philippe
  • Beckmann, Christian F.
  • Dawson, Gerard R.
  • Sommer, Bernd
  • Marston, Hugh M.
The current neuropsychiatric nosological categories underlie pragmatic treatment choice, regulation and clinical research but does not encompass biological rationale. However, subgroups of patients suffering from schizophrenia or Alzheimer's disease have more in common than the neuropsychiatric nature of their condition, such as the expression of social dysfunction. The PRISM project presents here initial quantitative biological insights allowing the first steps toward a novel trans-diagnostic classification of psychiatric and neurological symptomatology intended to reinvigorate drug discovery in this area. In this study, we applied spectral clustering on digital behavioural endpoints derived from passive smartphone monitoring data in a subgroup of Schizophrenia and Alzheimer's disease patients, as well as age matched healthy controls, as part of the PRISM clinical study. This analysis provided an objective social functioning characterization with three differential clusters that transcended initial diagnostic classification and was shown to be linked to quantitative neurobiological parameters assessed. This emerging quantitative framework will both offer new ways to classify individuals in biologically homogenous clusters irrespective of their initial diagnosis, and also offer insights into the pathophysiological mechanisms underlying these clusters, The PRISM project (www.prism-project.eu) leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA. This publication reflects only the authors’ views neither IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer’s disease

  • Saris, Ilja M.J.
  • Aghajani, Moji
  • Reus, Lianne M.
  • Visser, Pieter Jelle
  • Pijnenburg, Yolande
  • van der Wee, Nic J.A.
  • Bilderbeck, Amy C.
  • Raslescu, Andreea
  • Malik, Asad
  • Mennes, Maarten
  • Koops, Sanne
  • Arrango, Celso
  • Ayuso Mateos, José Luis
  • Dawson, Gerard R.
  • Marston, Hugh
  • Kas, Martien J.
  • Penninx, Brenda W.J.H.
Objectives: Social dysfunction is one of the most common signs of major neuropsychiatric disorders. The Default Mode Network (DMN) is crucially implicated in both psychopathology and social dysfunction, although the transdiagnostic properties of social dysfunction remains unknown. As part of the pan-European PRISM (Psychiatric Ratings using Intermediate Stratified Markers) project, we explored cross-disorder impact of social dysfunction on DMN connectivity. Methods: We studied DMN intrinsic functional connectivity in relation to social dysfunction by applying Independent Component Analysis and Dual Regression on resting-state fMRI data, among schizophrenia (SZ; N=48), Alzheimer disease (AD; N=47) patients and healthy controls (HC; N=55). Social dysfunction was operationalised via the Social Functioning Scale (SFS) and De Jong-Gierveld Loneliness Scale (LON). Results: Both SFS and LON were independently associated with diminished DMN connectional integrity within rostromedial prefrontal DMN subterritories (pcorrected range=0.02–0.04). The combined effect of these indicators (Mean.SFS + LON) on diminished DMN connectivity was even more pronounced (both spatially and statistically), independent of diagnostic status, and not confounded by key clinical or sociodemographic effects, comprising large sections of rostromedial and dorsomedial prefrontal cortex (pcorrected =0.01). Conclusions: These findings pinpoint DMN connectional alterations as putative transdiagnostic endophenotypes for social dysfunction and could aid personalised care initiatives grounded in social behaviour, The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This publication reflects only the author’s views and neither the IMI 2JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein
Docta Complutense
Publication Artículo científico (JournalArticle)

Assessment of school anti-bullying interventions: A Meta-analysis of randomized clinical trials

  • Fraguas Herráez, David
  • Díaz Caneja, Covadonga M.
  • Ayora, Miriam
  • Durán Cutilla, Manuel
  • Abregú Crespo, Renzo
  • Ezquiaga Bravo, Iciar
  • Martín Babarro, Javier
  • Arango López, Celso
Importance: Bullying is a prevalent and modifiable risk factor for mental health disorders. Although previous studies have supported the effectiveness of anti-bullying programs; their population impact and the association of specific moderators with outcomes are still unclear. Objective: To assess the effectiveness of school anti-bullying interventions, their population impact, and the association between moderator variables and outcomes. Data Sources: A search of Ovid MEDLINE, ERIC, and PsycInfo databases was conducted using 3 sets of search terms to identify randomized clinical trials (RCTs) assessing anti-bullying interventions published from database inception through February 2020. A manual search of reference lists of articles included in previous systematic reviews and meta-analyses was also performed. Study Selection: The initial literature search yielded 34 798 studies. Included in the study were articles that (1) assessed bullying at school; (2) assessed the effectiveness of an anti-bullying program; (3) had an RCT design; (4) reported results; and (5) were published in English. Of 16 707 studies identified, 371 met the criteria for review of full-text articles; 77 RCTs were identified that reported data allowing calculation of effect sizes (ESs). Of these, 69 independent trials were included in the final meta-analysis database. Data Extraction and Synthesis: Random-effects and meta-regression models were used to derive Cohen d values with pooled 95% CIs as estimates of ES and to test associations between moderator variables and ES estimates. Population impact number (PIN), defined as the number of children in the total population for whom 1 event may be prevented by an intervention, was used as an estimate of the population impact of universal interventions targeting all students, regardless of individual risk. Main Outcomes and Measures: The main outcomes are the effectiveness (measured by ES) and the population impact (measured by the PIN) of anti-bullying interventions on the following 8 variable categories: Overall bullying, bullying perpetration, bullying exposure, cyberbullying, attitudes that discourage bullying, attitudes that encourage bullying, mental health problems (eg, anxiety and depression), and school climate as well as the assessment of potential assocations between trial or intervention characteristics and outcomes. Results: This study included 77 samples from 69 RCTs (111659 participants [56511 in the intervention group and 55148 in the control group]). The weighted mean (range) age of participants in the intervention group was 11.1 (4-17) years and 10.8 (4-17) years in the control group. The weighted mean (range) proportion of female participants in the intervention group was 49.9% (0%-100%) and 50.5% (0%-100%) in the control group. Anti-bullying interventions were efficacious in reducing bullying (ES,-0.150; 95% CI,-0.191 to-0.109) and improving mental health problems (ES,-0.205; 95% CI,-0.277 to-0.133) at study end point, with PINs for universal interventions that target the total student population of 147 (95% CI, 113-213) and 107 (95% CI, 73-173), respectively. Duration of intervention was not statistically significantly associated with intervention effectiveness (mean [range] duration of interventions, 29.4 [1 to 144] weeks). The effectiveness of anti-bullying programs did not diminish over time during follow-up (mean [range] follow-up, 30.9 [2-104] weeks). Conclusions and Relevance: Despite the small ESs and some regional differences in effectiveness, the population impact of school anti-bullying interventions appeared to be substantial. Better designed trials that assess optimal intervention timing and duration are warranted.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

La psiquiatría post-COVID-19

  • Vieta, Eduard
  • Pérez Solà, Víctor
  • Arango, Celso
EV would like to thank the Ministry of Science and Research (PI15/00283, PI18/00805) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), the Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 1365), and project SLT006/17/00357 of the Strategic Plan for Health Research and Innovation (PERIS) 2016–2020 (Department of Health), CERCA PROGRAM, Government of Catalonia. VP would like to thank the Ministry of Science and Research (PI19/00236) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), CIBERSAM G21. Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 134), CERCA Program, Government of Catalonia. CA has received support from the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by the European Commission's ERDF Fund, “A way of making Europe,” CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No. 115916, Project PRISM, and grant agreement No. 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, and Fundación Alicia Koplowitz.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis.

  • Solanes Font, Aleix
  • Mezquida, Gisela
  • Janssen, Joost
  • Amoretti, Silvia
  • Lobo, Antonio
  • González Pinto Arrillaga, Ana María
  • Arango, Celso
  • Vieta, Eduard
  • Castro Fornieles, Josefina
  • Bergé, Daniel
  • Albacete, Auria
  • Giné, Eloi
  • Parellada, Mara
  • Bernardo, Miguel
  • PEPs Group
  • Pomarol Clotet, Edith
  • Radua, Joaquim
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18-24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio=4.58, P<0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software., We would also like to thank the Instituto de Salud Carlos III, the Spanish Ministry of Science, Innovation, and Universities, the European Regional Development Fund (ERDF/FEDER), European Social Fund, “Investing in your future”, “A way of making Europe” (projects: PI08/0208, PI11/00325, PI14/00292, PI14/00612, PI14/01148, PI14/01151, PI17/00481, PI17/01997, PI18/01055, PI19/00394, PI19/00766, PI20/00721, PI20/01342, and PI21/00713; contracts: CP14/00041, JR19/00024, CPII19/00009, and CD20/00177); CERCA Program; Catalan Government, the Secretariat of Universities and Research of the Department of Enterprise and Knowledge (2017SGR01271, 2017SGR1355, and 2017SGR1365); Institut de Neurociències, Universitat de Barcelona; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2); the University of the Basque Country (2019 321218ELCY GIC18/107); the Basque Government (2017111104); European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. The funding organizations played no role in the study design, data collection, analysis, or manuscript approval.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis

  • Molina García, Mariola
  • Fraguas, David
  • Del Rey Mejías, Ángel
  • Mezquida, Gisela
  • Sánchez Torres, Ana María
  • Amoretti, Silvia
  • Lobo, Antonio
  • González Pinto Arrillaga, Ana María
  • Andreu Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta, Eduard
  • Baeza, Immaculada
  • Mané, Anna
  • Cuesta, Manuel
  • de la Serna, Elena
  • Payá, Beatriz
  • Zorrilla Martínez, Iñaki
  • Arango, Celso
  • Bernardo, Miquel
  • Rapado-Castro, Marta
  • Parellada, Mara
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III, PI02/1248, PI03032, PI05/0678, PI08/0208 PI09/01442, PI11/00325, PI12/1303, PI14/00612, PI15/00723, PI17/009977, PI18/00753 cofinanced by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2). The CERCA Program/Generalitat de Catalunya And Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l’any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l’atenció primària, amb el codi d’expedient SLT006/17/00345. European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz Caneja, Covadonga
  • Costas, Javier
  • de Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás, Lourdes
  • Bobes, Julio
  • González Pinto Arrillaga, Ana María
  • Crespo Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, María Dolores
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango, Celso
  • González Peñas, Javier
[EN] Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N=3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN), and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. We are grateful to Paloma Pantoja for her assistance in the design of the figures. A.A.-B. holds a Rio Hortega Grant from Instituto de Salud Carlos III (CM20/00114). C.M.D.-C. holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024).
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Cortical thinning over two years after first-episode psychosis depends on age of onset.

  • Pina Camacho, Laura
  • Martínez, Kenia
  • Díaz Caneja, Covadonga
  • Mezquida, Gisela
  • Cuesta, Manuel J.
  • Moreno, Carmen
  • Amoretti, Silvia
  • González Pinto Arrillaga, Ana María
  • Arango, Celso
  • Vieta, Eduard
  • Castro Fornieles, Josefina
  • Lobo, Antonio
  • Fraguas, David
  • Bernardo, Miguel
  • Janssen, Joost
  • Parellada, Mara
  • Zorrilla Martínez, Iñaki
  • PEPs Group
[EN] First-episode psychosis (FEP) patients show structural brain abnormalities at the first episode. Whether the cortical changes that follow a FEP are progressive and whether age at onset modulates these changes remains unclear. This is a multicenter MRI study in a deeply phenotyped sample of 74 FEP patients with a wide age range at onset (15-35 years) and 64 neurotypical healthy controls (HC). All participants underwent two MRI scans with a 2-year follow-up interval. We computed the longitudinal percentage of change (PC) for cortical thickness (CT), surface area (CSA) and volume (CV) for frontal, temporal, parietal and occipital lobes. We used general linear models to assess group differences in PC as a function of age at FEP. We conducted post-hoc analyses for metrics where PC differed as a function of age at onset. We found a significant age-by-diagnosis interaction effect for PC of temporal lobe CT (d=0.54; p=002). In a post-hoc-analysis, adolescent-onset (≤19y) FEP showed more severe longitudinal cortical thinning in the temporal lobe than adolescent HC. We did not find this difference in adult-onset FEP compared to adult HC. Our study suggests that, in individuals with psychosis, CT changes that follow the FEP are dependent on the age at first episode, with those with an earlier onset showing more pronounced cortical thinning in the temporal lobe., We are extremely grateful to all subjects who took part in this study. This work was supported by CIBERSAM; Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI081203, PI08/0208; PI11/00325; PI1101686, PI14/00612, PI17/01997, PI20/01342), co‐financed by the ERDF from the European Commission “A way of making Europe”, European Union Seventh Framework Program (FP7- HEALTH-2013-2.2.1-2-603196 [Project PSYSCAN]), EU H2020 (IMI‐2 Joint Undertaking under grant agreements 115916 (project PRISM) and 777394 (project AIMS‐2‐TRIALS)), Madrid Regional Government (S2017/BMD‐3740, and AGES-CM-2-CM) and European Union Structural Funds; Fundación Familia Alonso, Fundacion Mutua Madrileña, and Fundación Alicia Koplowitz.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • De Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás Saura, Lourdes
  • Bobes García, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, M. Dolors
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango López, Celso
  • González-Peñas, Javier
Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N = 3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis

  • Molina García, Mariola
  • Fraguas, David
  • Del Rey Mejias, Angel
  • Mezquida Mateos, Gisela
  • Sánchez-Torres, Ana M.
  • Amoretti Guadall, Silvia
  • Lobo, Antonio
  • González-Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta i Pascual, Eduard, 1963-
  • Baeza, Inmaculada, 1970-
  • Mané Santacana, Anna
  • Cuesta, Manuel J.
  • Serna, Elena de la, 1978-
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo Arroyo, Miquel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mapping genomic loci implicates genes and synaptic biology in schizophrenia

  • Trubetskoy, Vassily
  • Pardiñas, Antonio F.
  • Qi, Ting
  • Panagiotaropoulou, Georgia
  • Awasthi, Swapnil
  • Bigdeli, Tim B.
  • Bryois, Julien
  • Chen, Chia-Yen
  • Dennison, Charlotte A.
  • Hall, Lynsey S.
  • Lam, Max
  • Curtis, Charles
  • Nikitina-Zake, Liene
  • Davidson, Michael
  • Joa, Inge
  • Davis, Kenneth L.
  • Yolken, Robert
  • Murray, Robin M.
  • de Haan, Lieuwe
  • Legge, Sophie E.
  • Serretti, Alessandro
  • van Os, Jim
  • Smoller, Jordan W.
  • Agartz, Ingrid
  • Alizadeh, Behrooz Z.
  • Degenhardt, Franziska
  • DeLisi, Lynn E.
  • Demontis, Ditte
  • Dickerson, Faith
  • Zai, Clement C.
  • Dikeos, Dimitris
  • Dinan, Timothy
  • Henskens, Frans A.
  • Vaaler, Arne
  • Noto, Cristiano
  • Nimgaonkar, Vishwajit
  • Rautanen, Anna
  • Lehrer, Douglas S.
  • Djurovic, Srdjan
  • Duan, Jubao
  • Julià, Antonio
  • Stahl, Eli A.
  • Zhou, Wei
  • Vawter, Marquis P.
  • Toncheva, Draga
  • Webb, Bradley T.
  • Ducci, Giuseppe
  • Dudbridge, Frank
  • Eriksson, Johan G.
  • Fañanas Saura, Lourdes
  • Goldstein, Jacqueline I.
  • Faraone, Stephen V.
  • Lencer, Rebecca
  • Moreno, Carmen
  • Bacanu, Silviu A.
  • Fiorentino, Alessia
  • Calkins, Monica E.
  • Mitjans, Marina
  • Forstner, Andreas
  • Nuechterlein, Keith H.
  • Frank, Josef
  • Tsuang, Debby W.
  • Freimer, Nelson B.
  • Tooney, Paul A.
  • Belangero, Sintia Iole
  • Weinberger, Daniel R.
  • Fromer, Menachem
  • Ge,Tian
  • Adolfsson, Rolf
  • Hakonarson, Hakon
  • Zhu, Feng
  • Frustaci, Alessandra
  • Nöthen, Markus M.
  • Gadelha, Ary
  • Genovese, Giulio
  • Gershon, Elliot S.
  • Quattrone, Diego
  • Kähler, Anna K.
  • Kam-Thong, Tony
  • van Amelsvoort, Therese
  • Vilella, Elisabet
  • Molden, Espen
  • O'Brien, Niamh Louise
  • Zimprich, Fritz
  • Kamatani, Yoichiro
  • Braun, Alice
  • Melegh, Bela
  • Pirinen, Matti
  • Karachanak-Yankova, Sena
  • Ophoff, Roel A.
  • Kebir, Oussama
  • Lerer, Bernard
  • Nordentoft, Merete
  • Fanous, Ayman H.
  • Reichenberg, Abraham
  • Li, Miaoxin
  • Periyasamy, Sathish
  • Lieberman, Jeffrey
  • Werge, Thomas
  • Light, Gregory A.
  • Limborska, Svetlana
  • Tosato, Sarah
  • Liu, Chih-Min
  • Olincy, Ann
  • Magnusson, Sigurdur
  • Gareeva, Anna
  • Bressan, Rodrigo Affonseca
  • Lönnqvist, Jouko
  • Roe, Cheryl
  • Cheng, Wei
  • Athanasiu, Lavinia
  • Gutiérrez, Blanca
  • Harvey, Carol
  • Loughland, Carmel M.
  • Lubinski, Jan
  • Luykx, Jurjen J.
  • Lynham, Amy
  • Gawlik, Micha
  • Macek, Milan
  • Mackinnon, Andrew
  • Buxbaum, Joseph D.
  • Tura, Gian Battista
  • Bromet, Evelyn J.
  • Atbaşoğlu, Eşref Cem
  • Roffman, Joshua L.
  • Magnusson, Patrik K. E.
  • Maher, Brion S.
  • Ota, Vanessa Kiyomi
  • Paciga, Sara A.
  • Gejman, Pablo V.
  • Arango, Celso
  • Forti, Marta Di
  • Maier, Wolfgang
  • Richards, Alexander L.
  • Malaspina, Dolores
  • Mallet, Jacques
  • Metspalu, Andres
  • Marder, Stephen R.
  • Li, Zhiqiang
  • Takahashi, Atsushi
  • Marsal, Sara
  • Kučinskiene, Zita Ausrele
  • Suvisaari, Jaana
  • Martin, Alicia R.
  • Turetsky, Bruce I.
  • Martorell, Lourdes
  • Palotie, Aarno
  • Mattheisen, Manuel
  • Baune, Bernhard T.
  • Saka, Meram C.
  • McCarley, Robert W.
  • Giusti-Rodríguez, Paola
  • Riley, Brien P.
  • Murphy, Kieran C.
  • Gill, Michael
  • McDonald, Colm
  • Bruggeman, Richard
  • McGrath, John J.
  • Sidorenko, Julia
  • Medeiros, Helena
  • Pantelis, Christos
  • Grove, Jakob
  • Campion, Dominique
  • Pato, Carlos N.
  • Svrakic, Dragan M.
  • Üçok, Alp
  • Glatt, Stephen J.
  • Papadimitriou, George N.
  • Khrunin, Andrey
  • Straub, Richard E.
  • Parellada, Mara
  • Buckley, Peter F.
  • Paunio, Tiina
  • Roth, Julian
  • Morgan, Vera A.
  • Wildenauer, Dieter B.
  • Ayub, Muhammad
  • Rothermundt, Matthias
  • Weiser, Mark
  • Rutten, Bart P. F.
  • Saker-Delye, Safaa
  • Salomaa, Veikko
  • Børglum, Anders D.
  • Sanjuán, Julio
  • van Winkel, Ruud
  • González Peñas, Javier
  • Yu, Xin
  • Kim, Sung-Wan
  • Santoro, Marcos Leite
  • Benner, Christian
  • Ikeda, Masashi
  • Morley, Christopher P.
  • Zeng, Jian
  • Savitz, Adam
  • Schall, Ulrich
  • Scott, Rodney J.
  • Voloudakis, Georgios
  • Yue, Weihua
  • Seidman, Larry J.
  • Sharp, Sally Isabel
  • Alptekin, Köksal
  • Klovins, Janis
  • Amin, Farooq
  • Bertolino, Alessandro
  • Shi, Jianxin
  • Siever, Larry J.
  • Atkinson, Elizabeth G.
  • Buckner, Randy L.
  • Holmans, Peter A.
  • Rivera, Margarita
  • Sigurdsson, Engilbert
  • González-Pinto, Ana
  • Sim, Kang
  • Skarabis, Nora
  • Stroup, T Scott
  • Slominsky, Petr
  • Guillin, Olivier
  • Wang, Shi-Heng
  • So, Hon-Cheong
  • Quested, Digby
  • Sobell, Janet L.
  • Braff, David
  • Zhang, Wen
  • Bybjerg-Grauholm, Jonas
  • Söderman, Erik
  • Rujescu, Dan
  • Chambert, Kimberley D.
  • Stain, Helen J.
  • Melle, Ingrid
  • Carr, Vaughan J.
  • Pocklington, Andrew J.
  • Steen, Nils Eiel
  • Harwood, Janet
  • Steixner-Kumar, Agnes A.
  • Gopal, Srihari
  • Stögmann, Elisabeth
  • Veijola, Juha
  • Watanabe, Kyoko
  • Sham, Pak C.
  • Cahn, Wiepke
  • Bramon, Elvira
  • Roussos, Panos
  • Waddington, John
  • Perkins, Diana O.
  • Pato, Michele T.
  • Walter, Henrik
  • Kondratiev, Nikolay
  • Waterreus, Anna
  • Al Eissa, Mariam
  • Bobes, Julio
  • Golimbet, Vera
  • Black, Donald W.
  • Als, Thomas D.
  • Bray, Nicholas J.
  • Breen, Gerome
  • Buccola, Nancy G.
  • Sanders, Alan R.
  • Byerley, William F.
  • Cervilla, Jorge A.
  • Michie, Patricia T.
  • Pfuhlmann, Bruno
  • Chen, Wei J.
  • Hong, Kyung Sue
  • O'Neill, F Anthony
  • Terao, Chikashi
  • Green, Michael F.
  • Cloninger, C. Robert
  • Crespo-Facorro, Benedicto
  • Donohoe, Gary
  • Gülöksüz, Sinan
  • Freedman, Robert
  • Albus, Margot
  • Hayward, Caroline
  • Pietiläinen, Olli
  • Herms, Stefan
  • Hultman, Christina M.
  • Galletly, Cherrie
  • Gandal, Michael J.
  • Hahn, Eric
  • Konte, Bettina
  • Castle, David
  • Gennarelli, Massimo
  • Milani, Lili
  • Hougaard, David M.
  • Hwu, Hai-Gwo
  • Pulver, Ann E.
  • Jablensky, Assen V.
  • Molina, Esther
  • Qin, Shengying
  • McCarroll, Steven A.
  • Moran, Jennifer L.
  • Azevedo, Maria Helena
  • Gur, Rachel E.
  • Kraft, Julia
  • Mors, Ole
  • Catts, Stanley V.
  • Lazzeroni, Laura C.
  • Mortensen, Preben B.
  • Streit, Fabian
  • Kusumawardhani, Agung
  • Alexander, Madeline
  • Godard, Stephanie
  • Müller-Myhsok, Bertram
  • Milanova, Vihra
  • Neil, Amanda L.
  • Cichon, Sven
  • Giannitelli, Marianna
  • Cheung, Eric F. C.
  • Kubo, Michiaki
  • Schwab, Sibylle G.
  • Collier, David A.
  • Williams, Nigel M.
  • Morris, Derek W.
  • Corvin, Aiden
  • Pimm, Jonathan
  • Curtis, David
  • Haroutunian, Vahram
  • Keller, Matthew C.
  • Vassos, Evangelos
  • Hyman, Steven E.
  • Iwata, Nakao
  • Jönsson, Erik G.
  • Kahn, René S.
  • Chan, Raymond C. K.
  • Kennedy, James L.
  • Shi, Yongyong
  • Adams, Mark
  • Witt, Stephanie H.
  • Khusnutdinova, Elza
  • Verhage, Matthijs
  • Xu, Shuhua
  • Wu, Yang
  • Kirov, George
  • Arolt, Volker
  • Knowles, James A.
  • Moltó, Maria Dolores
  • Krebs, Marie-Odile
  • Hartmann, Annette M.
  • Nestadt, Gerald
  • Wormley, Brandon K.
  • Bass, Nicholas J.
  • Laurent-Levinson, Claudine
  • Lee, Jimmy
  • Muntané, Gerard
  • Porteous, David
  • Kuzelova-Ptackova, Hana
  • Lencz, Todd
  • Subramaniam, Mythily
  • Levinson, Douglas F.
  • Li, Qingqin S.
  • Liu, Jianjun
  • Swerdlow, Neal R.
  • Cairns, Murray J.
  • Malhotra, Anil K.
  • Malhotra, Dheeraj
  • Iyegbe, Conrad
  • Mondelli, Valeria
  • Kim, Minsoo
  • Arrojo, Manuel
  • Landi, Stefano
  • McIntosh, Andrew M.
  • Petryshen, Tracey L.
  • Radant, Allen D.
  • Frei, Oleksandr
  • Mesholam-Gately, Raquelle I.
  • McQuillin, Andrew
  • Sugar, Catherine A.
  • Menezes, Paulo Rossi
  • St Clair, David
  • Meier, Sandra
  • Powell, John
  • Chaumette, Boris
  • Stefansson, Hreinn
  • Domenici, Enrico
  • Bonassi, Stefano
  • Stefánsson, Kári
  • Wu, Jing Qin
  • Tsuang, Ming T.
  • Myin-Germeys, Inez
  • Pellegrino, Renata
  • Visscher, Peter M.
  • Yang, Jian
  • Posthuma, Danielle
  • Andreassen, Ole A.
  • Koopmans, Frank
  • Kendler, Kenneth S.
  • Chong, Siow Ann
  • Gur, Ruben C.
  • Ehrenreich, Hannelore
  • Owen, Michael J.
  • Rietschel, Marcella
  • Gratten, Jacob
  • Wray, Naomi R.
  • Hoffmann, Per
  • Daly, Mark J.
  • Szatkiewicz, Jin P.
  • Huang, Hailiang
  • Nenadić, Igor
  • Torretta, Silvia
  • Escott-Price, Valentina
  • Neale, Benjamin M.
  • Begemann, Martin
  • Thibaut, Florence
  • Agerbo, Esben
  • Rampino, Antonio
  • Sullivan, Patrick F.
  • Schulze, Thomas G.
  • Ripke, Stephan
  • Walters, James T. R.
  • O'Donovan, Michael C.
  • Kučinskas, Vaidutis
  • Belliveau, Richard A.
  • Bene, Judit
  • Oh, Sang-Yun
  • Ta, Thi Minh Tam
  • Greenwood, Tiffany A.
  • Howrigan, Daniel P.
  • Rapaport, Mark H.
  • Benyamin, Beben
  • Mowry, Bryan J.
  • Giegling, Ina
  • Strengman, Eric
  • Bergen, Sarah E.
  • Silverman, Jeremy M.
  • Blasi, Giuseppe
  • Cohen, David
  • Stone, William S.
  • Xu, Zhida
  • Lee, Phil H.
  • Consoli, Angèle
  • Kelly, Brian
  • Cordeiro, Quirino
  • Esko, Tõnu
  • Costas, Javier
Schizophrenia has a heritability of 60-80%1, much of which is attributable to common risk alleles. Here, in a two-stage genome-wide association study of up to 76,755 individuals with schizophrenia and 243,649 control individuals, we report common variant associations at 287 distinct genomic loci. Associations were concentrated in genes that are expressed in excitatory and inhibitory neurons of the central nervous system, but not in other tissues or cell types. Using fine-mapping and functional genomic data, we identify 120 genes (106 protein-coding) that are likely to underpin associations at some of these loci, including 16 genes with credible causal non-synonymous or untranslated region variation. We also implicate fundamental processes related to neuronal function, including synaptic organization, differentiation and transmission. Fine-mapped candidates were enriched for genes associated with rare disruptive coding variants in people with schizophrenia, including the glutamate receptor subunit GRIN2A and transcription factor SP4, and were also enriched for genes implicated by such variants in neurodevelopmental disorders. We identify biological processes relevant to schizophrenia pathophysiology; show convergence of common and rare variant associations in schizophrenia and neurodevelopmental disorders; and provide a resource of prioritized genes and variants to advance mechanistic studies., The work at Cardiff University was additionally supported by Medical Research Council Centre grant no. MR/L010305/1 and program grant no. G0800509. S. Xu also gratefully acknowledges the support of the National Natural Science Foundation of China (NSFC) grants (31525014, 91731303, 31771388, 31961130380 and 32041008), the UK Royal Society-Newton Advanced Fellowship (NAF\R1\191094), the Key Research Program of Frontier Sciences (QYZDJ-SSW-SYS009) and the Strategic Priority Research Program (XDB38000000) of the Chinese Academy of Sciences, and the Shanghai Municipal Science and Technology Major Project (2017SHZDZX01). O. A. Andreassen was supported by the Research Council of Norway (283798, 262656, 248980, 273291, 248828, 248778, 223273); KG Jebsen Stiftelsen, South-East Norway Health Authority, EU H2020 no. 847776. B. Melegh was supported in part by the National Scientific Research Program (NKFIH) K 138669. S. V. Faraone is supported by the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 602805, the European Union’s Horizon 2020 research and innovation programme under grant agreements 667302 and 728018 and NIMH grants 5R01MH101519 and U01 MH109536-01. S. I. Belangero was supported by FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo), grant numbers: 2010/08968-6; 2014/07280-1 2011/50740-5 (including R. A. Bressan). The Singapore team (J. Lee, J. Liu, K. Sim, S. A. Chong and M. Subramanian) acknowledges the National Medical Research Council Translational and Clinical Research Flagship Programme (grant no.: NMRC/TCR/003/2008). M. Macek was supported by LM2018132, CZ.02.1.01/0.0/0.0/18_046/0015515 and IP6003 –VZFNM00064203. C. Arango has been funded by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement no 115916, project PRISM; and grant agreement no. 777394, project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz. E. Bramon acknowledges support from the National Institute of Health Research UK (grant NIHR200756); Mental Health Research UK John Grace QC Scholarship 2018; an ESRC collaborative award 2020; BMA Margaret Temple Fellowship 2016; Medical Research Council New Investigator Award (G0901310); MRC Centenary Award (G1100583); MRC project grant G1100583; National Institute of Health Research UK post-doctoral fellowship (PDA/02/06/016); NARSAD Young Investigator awards 2005 and 2008; Wellcome Trust Research Training Fellowship; Wellcome Trust Case Control Consortium awards (085475/B/08/Z, 085475/Z/08/Z); European Commission Horizon 2020 (747429); NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King’s College London; and NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London (UCLH BRC - Mental Health Theme). D. Molto is funded by the European Regional Development Fund (ERDF)–Valencian Community 2014–2020, Spain. E. G. Atkinson was supported by the NIMH K01MH121659., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Childhood Maltreatment, Educational Attainment, and IQ: Findings From a Multicentric Case-control Study of First-episode Psychosis (EU-GEI)

  • Sideli, Lucia
  • Schimmenti, Adriano
  • La Barbera, Daniele
  • La Cascia, Caterina
  • Ferraro, Laura
  • Aas, Monica
  • Alameda, Luis
  • Velthorst, Eva
  • Fisher, Helen L.
  • Caretti, Vincenzo
  • Trotta, Giulia
  • Tripoli, Giada
  • Quattrone, Diego
  • Gayer-Anderson, Charlotte
  • Seminerio, Fabio
  • Sartorio, Crocettarachele
  • Marrazzo, Giovanna
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Tarricone, Ilaria
  • Berardi, Domenico
  • D'Andrea, Giuseppe
  • Arango, Celso
  • Arrojo, Manuel
  • Bernardo, Miguel
  • Bobes, Julio
  • Sanjuán, Julio
  • Santos, José Luis
  • Menezes, Paulo Rossi
  • Del-Ben, Cristina Marta
  • Jongsma, Hannah E.
  • Jones, Peter B.
  • Kirkbride, James B.
  • Llorca, Pierre-Michel
  • Tortelli, Andrea
  • Pignon, Baptiste
  • de Haan, Lieuwe
  • Selten, Jean-Paul
  • Van Os, Jim
  • Rutten, Bart P. F.
  • Di Forti, Marta
  • Morgan, Craig
  • Murray, Robin M.
[Background and hypothesis] Evidence suggests that childhood maltreatment (ie, childhood abuse and childhood neglect) affects educational attainment and cognition. However, the association between childhood maltreatment and Intelligence Quotient (IQ) seems stronger among controls compared to people with psychosis. We hypothesised that: the association between childhood maltreatment and poor cognition would be stronger among community controls than among people with first-episode of psychosis (FEP); compared to abuse, neglect would show stronger associations with educational attainment and cognition; the association between childhood maltreatment and IQ would be partially accounted for by other risk factors; and the association between childhood maltreatment, educational attainment, and IQ would be stronger among patients with affective psychoses compared to those with nonaffective psychoses., [Study Design] 829 patients with FEP and 1283 community controls from 16 EU-GEI sites were assessed for child maltreatment, education attainment, and IQ., [Study Results] In both the FEP and control group, childhood maltreatment was associated with lower educational attainment. The association between childhood maltreatment and lower IQ was robust to adjustment for confounders only among controls. Whereas childhood neglect was consistently associated with lower attainment and IQ in both groups, childhood abuse was associated with IQ only in controls. Among both patients with affective and nonaffective psychoses, negative associations between childhood maltreatment and educational attainment were observed, but the crude association with IQ was only evident in affective psychoses., [Conclusions] Our findings underscore the role of childhood maltreatment in shaping academic outcomes and cognition of people with FEP as well as controls., The EU-GEI Study is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme, and Grant 2012/0417-0 from the São Paulo Research Foundation. B.P.F. Rutten is funded by a VIDI award (no. 91.718.336) from the Netherlands Scientific Organization. H. L. Fisher, C. Gayer-Anderson, and C. Morgan are supported by the Economic and Social Research Council (ESRC) Centre for Society and Mental Health at King’s College London [ES/S012567/1]. C. Arango has received support by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements, FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz. J.B. Kirkbride is supported by the NIHR University College London Hospital Biomedical Research Centre., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genetic variants associated with longitudinal changes in brain structure across the lifespan

  • Brouwer, Rachel M.
  • Tordesillas-Gutiérrez, Diana
  • Crespo-Facorro, Benedicto
  • Hulshoff Pol, Hilleke E.
et al., Human brain structure changes throughout the lifespan. Altered brain growth or rates of decline are implicated in a vast range of psychiatric, developmental and neurodegenerative diseases. In this study, we identified common genetic variants that affect rates of brain growth or atrophy in what is, to our knowledge, the first genome-wide association meta-analysis of changes in brain morphology across the lifespan. Longitudinal magnetic resonance imaging data from 15,640 individuals were used to compute rates of change for 15 brain structures. The most robustly identified genes GPR139, DACH1 and APOE are associated with metabolic processes. We demonstrate global genetic overlap with depression, schizophrenia, cognitive functioning, insomnia, height, body mass index and smoking. Gene set findings implicate both early brain development and neurodegenerative processes in the rates of brain changes. Identifying variants involved in structural brain changes may help to determine biological pathways underlying optimal and dysfunctional brain development and aging., The ENIGMA-Plasticity Working Group is part of the ENIGMA World Aging Center, funded by NIA grants R56 AG058854 and R01 AG058854. The ENIGMA Consortium core funding was supported by NIH Consortium Grant U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centers of Excellence. 1000BRAINS: 1000BRAINS is a population-based cohort based on the Heinz-Nixdorf Recall Study and is supported, in part, by the German National Cohort. We thank the Heinz Nixdorf Foundation (Germany) for their generous support in terms of the Heinz Nixdorf Study. The authors are supported by the Initiative and Networking Fund of the Helmholtz Association (Svenja Caspers) and the European Union’s Horizon 2020 Research and Innovation Programme under grant agreements 785907 (Human Brain Project SGA2; Svenja Caspers, Sven Cichon and Katrin Amunts). This work was further supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders) under the auspices of the e:Med Program (grant 01ZX1314A; Sven Cichon) and by the Swiss National Science Foundation (SNSF, grant 156791; Sven Cichon). The authors acknowledge grants supporting their work from the European Union’s Horizon 2020 Research and Innovation Programme (H2020/2014–2020) under grant agreements 667302 (CoCA), 728018 (Eat2beNICE), 785907 (HBP SGA2) and 772376 (EScORIAL) and the Netherlands ALS Foundation.Additional support is received from the European Community’s Seventh Framework Programme (FP7/2007—2013) under grant agreements n° 602805 (Aggressotype), n° 603016 (MATRICS), n° 602450 (IMAGEMEND) and n° 278948 (TACTICS) and from the European Community’s Horizon 2020 Programme (H2020/2014—2020) under grant agreements n° 643051 (MiND) and n° 667302 (CoCA). FP7 Ideas: the European Research Council (ERC-230374 to D.B.). This work was supported by Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012 and PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement 115916, Project PRISM and grant agreement 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. The Horizon 2020 funded ERC Advanced Grant ‘STRATIFY’ (Brain network based stratification of reinforcement-related disorders) (695313). The FP7 project MATRICS (603016). The research leading to these results also received support from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement 278948 (TACTICS), 602805 (Aggressotype), 603016 (MATRICS) and 602450 (Imagemend) and the Innovation Medicine Initiative grants 115300 (EU-AIMS) and 777394 (AIMS-2-TRIALS).PAFIP: PAFIP was supported by the Instituto de Salud Carlos III (PI14/00639, PI14/00918 and PI17/01056) and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT025KG Jebsen Stiftelsen and H2020 CoMorMent (847776).34363). European Union Marie Curie Research Training Network (MRTN-CT-2006-035987)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium

  • Constantinides, Constantinos
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
  • Walton, Esther
C. Constantinides et al., Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years; range 18-72 years; 67% male) and 2598 healthy controls (mean age 33.8 years, range 18-73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]). On average, SZ patients showed a higher brain-PAD of +3.55 years (95% CI: 2.91, 4.19; I2 = 57.53%) compared to controls, after adjusting for age, sex and site (Cohen's d = 0.48). Among SZ patients, brain-PAD was not associated with specific clinical characteristics (age of onset, duration of illness, symptom severity, or antipsychotic use and dose). This large-scale collaborative study suggests advanced structural brain ageing in SZ. Longitudinal studies of SZ and a range of mental and somatic health outcomes will help to further evaluate the clinical implications of increased brain-PAD and its ability to be influenced by interventions., The ENIGMA Schizophrenia Working Group acknowledges the National Institutes of Health (NIH) Big Data to Knowledge (BD2K) award for foundational support and consortium development (Grant No. U54 EB020403 to PMT). CC was supported by grant MR/N0137941/1 for the GW4 BIOMED Doctoral Training Partnership awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/ UK Research & Innovation (UKRI). JHC was supported by a UKRI Innovation Fellowship (MR/R024790/2). LE was supported by Desert-Pacific Mental Illness Research Education and Clinical Center, US, NIH grant R01MH083968-05. TH was funded by the German Research Foundation (DFG grants HA7070/2-2, HA7070/3, HA7070/4 to TH). LH was supported by a Rubicon fellowship (grant number 452020227) provided by The Dutch Research Council (NWO). NJ and LS were supported by NIH grant R01 MH117601. NJ was also supported by NIH grants R01AG059874, R01MH11760. LS was also supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship (1140764) and a University of Melbourne Dame Kate Campbell fellowship. PMT was supported in part by NIH grant R01 MH116147. EW was supported by the European Union Horizon 2020 research and innovation programme (EarlyCause, grant number 848158). Acknowledgements for the various participating data contributors follow - ASRB: the Australian Schizophrenia Research Bank (ASRB) was supported by NHMRC (Enabling Grant, ID 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute. CP was also supported by a NHMRC Senior Principal Research Fellowship (1105825), an NHMRC L3 Investigator Grant (1196508). CSW was funded by the NSW Ministry of Health, Office of Health and Medical Research and a recipient of a National Health and Medical Research Council (Australia) Principal Research Fellowship (PRF) (#1117079). CAMH: the datasets were generated and shared with support from the CAMH Foundation and the Canadian Institutes of Health Research. CASSI: this study was supported by NHMRC grant 568807 (awarded to CSW and TW). CSW was funded by the NSW Ministry of Health, Office of Health and Medical Research and a recipient of a NHMRC (Australia) Principal Research Fellowship (PRF) (#1117079). COBRE: the study and investigators were supported by NIH grants R01MH118695, R01MH121101, as well as National Science Foundation (NSF) grant 2112455 (awarded to VC). JT (senior author) was supported by NIH grant R01MH121246. EONCKS: all processing of contributed neuroimaging data was conducted on the Centre for High Performance Computing, Cape Town, South Africa. ESO: the study and investigators (AC, FS, DT) was funded by the Ministry of Health, Czech Republic - Conceptual Development of Research Organization (Institute for Clinical and Experimental Medicine – IKEM, IN 00023001), and Ministry of Health of the Czech Republic, grants nr. NU20-04-00393 and NU21-08-00432. FBIRN: The study was supported by National Institutes of Health grant numbers: NIH 1 U24 RR021992 (Function Biomedical Informatics Research Network), NIH 1 U24 RR025736 (Biomedical Informatics Research Network Coordinating). FBIRN data was processed by the UCI High Performance Computing cluster supported by Joseph Farran, Harry Mangalam, and Adam Brenner and the NCRR and the National Center for Advancing Translational Sciences. JT (senior author) was also supported by NIH grant R01MH121246. FIDMAG: this study was supported by Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and the Catalonian Government, Generalitat de Catalunya (2017-SGR-1271 to EP-C from AGAUR). PFC was supported by a Sara Borrell contract (CD19/00149), funded by Instituto de Salud Carlos III, co-funded by the European Union (European Regional Development Fund/European Social Fund [ERDF/ESF], “Investing in your future”). FSLRome: the IRCCS Santa Lucia Foundation of Rome study (FSLRome) was partially supported by the Italian Ministry of Health (RC12-13-14-15A Grant) and by the European Commission ERA-Net NEURON joint transnational calI 2010 (European Research Projects on Mental Disorders: NEUCONNECT). GROUP: This work was supported by the Geestkracht program of the Dutch Health Research Council (ZON-MW, grant number: 10-000-1002), and the European Community’s Seventh Framework Program under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI). Huilong: this study was funded by the National Natural Science Foundation of China (81761128021;31671145;81401115;81401133), Beijing Municipal Science & Technology Commission grant (Z141107002514016) and Beijing Natural Science Foundation (7162087, Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding (XMLX201609; zylx201409). IGP: The Imaging Genetics in Psychosis (IGP) study was supported by NHMRC Project Grant APP630471, APP1051673, APP1081603 (awarded to MJG), and the Macquarie University’s ARC Centre of Excellence in Cognition and its Disorders (CE110001021). MJG was supported by an Australian Research Council Future Fellowship (FT0991511; 2009-13) and a R.D. Wright Biomedical Career Development Award from the NHMRC (1061875; 2014-17). IMH: this study was supported by the National Healthcare Group, Singapore (SIG/05004; SIG/05028) and the Singapore Bioimaging Consortium (RP C009/06) research grants (awarded to KS). iRELATE: this study was supported by grants to GD from the European Research Council (ERC-2015-STG-677467) and Science Foundation Ireland (SFI-16/ERCS/3787). JBNU: YC was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant no. HI18C2383). Madrid: this research was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (grants SAM16PE07CP1, PI16/02012, and PI19/01024 awarded to CAra; PI17/01249 awarded JJ; and PI17/00481, JR19/00024 and PI20/00721 awarded to CMD-C), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2 awarded to CAra), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY) awarded to Cara; and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS awarded to CAra), Fundación Familia Alonso and Fundación Alicia Koplowitz. MCIC: this work was primarily supported by the Department of Energy (DE-FG02- 99ER62764) and the Mind Research Network. VC was also supported by NSF (grant no. 2112455) and NIH (grant no. R01MH118695, R01MH121101). MPRC: support was received from NIH grants R01MH123163, R01EB015611, R01NS114628 (awarded to PK). PAFIP: this study has been funded by Instituto de Salud Carlos III through the project PI17/01056 (co-funded by ERDF/ESF “A way to make Europe”/“Investing in your future”). RSCZ: the study was supported by National Institutes of Health grant number: NIMH R21MH097196 to TGMvE. SCORE: this study was supported in part by grant 3232BO_119382 from the Swiss National Science Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium

  • Schijven, Dick
  • Postema, Merel C.
  • Fukunaga, Masaki
  • Tordesillas-Gutiérrez, Diana
  • Crespo-Facorro, Benedicto
  • Francks, Clyde
ENIGMA consortium: et al., Left-right asymmetry is an important organizing feature of the healthy brain that may be altered in schizophrenia, but most studies have used relatively small samples and heterogeneous approaches, resulting in equivocal findings. We carried out the largest case-control study of structural brain asymmetries in schizophrenia, with MRI data from 5,080 affected individuals and 6,015 controls across 46 datasets, using a single image analysis protocol. Asymmetry indexes were calculated for global and regional cortical thickness, surface area, and subcortical volume measures. Differences of asymmetry were calculated between affected individuals and controls per dataset, and effect sizes were meta-analyzed across datasets. Small average case-control differences were observed for thickness asymmetries of the rostral anterior cingulate and the middle temporal gyrus, both driven by thinner left-hemispheric cortices in schizophrenia. Analyses of these asymmetries with respect to the use of antipsychotic medication and other clinical variables did not show any significant associations. Assessment of age- and sex-specific effects revealed a stronger average leftward asymmetry of pallidum volume between older cases and controls. Case-control differences in a multivariate context were assessed in a subset of the data (N = 2,029), which revealed that 7% of the variance across all structural asymmetries was explained by case-control status. Subtle case-control differences of brain macrostructural asymmetry may reflect differences at the molecular, cytoarchitectonic, or circuit levels that have functional relevance for the disorder. Reduced left middle temporal cortical thickness is consistent with altered left-hemisphere language network organization in schizophrenia., The ENIGMA project is in part supported by the National Institute of Biomedical Imaging and Bioengineering of the NIH (U54EB020403). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Individual Funding Sources: D.S., M.C.P., S.E.F., and C.F.: Max Planck Society (Germany). R.A.-A.: Miguel Servet contract from the Carlos III Health Institute (CP18/00003). J.V.-B.: Instituto de Investigación Sanitaria Valdecilla (IDIVAL) (INT/A21/10, INT/A20/04). D.A.: South-Eastern Norway Regional Health Authority (2019107, 2020086). L.T.W.: Research Council of Norway (223273, 300767), South-Eastern Norway Regional Health Authority (2019101), and European Research Council under the European Union’s Horizon 2020 Research and Innovation Program (ERC StG, 802998). O.A.A.: Research Council of Norway (223273, 275054), KG Jebsen Stiftelsen, South East Norway Health Authority (2017-112, 2019-108). P.K.: NIH (R01MH123163, R01EB015611). M.J.G.: National Health and Medical Research Council (NHMRC) (630471, 1051672, 1081603). C.P.: NHMRC Senior Principal Research Fellowship (1105825), NHMRC L3 Investigator Grant (1196508). V.D.C.: NIH (R01MH118695), NSF (2112455). J.M.F.: Senior Research Career Scientist Award, Department of Veterans Affairs. P.F.-C.: Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Instituto de Salud Carlos III, cofunded by European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF), “Investing in your future”): Sara Borrell Research contract (CD19/00149). G.S.: Italian Ministry of Health (RC17-18-19-20-21/A). A.N.V.: National Institute of Mental Health (NIMH), Canadian Institutes of Health Research (CIHR), Canada Foundation for Innovation, Centre for Addiction and Mental Health (CAMH) Foundation, University of Toronto. Y.-C.C.: Korean Mental Health Technology R&D Project (HL19C0015) and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI18C2383), funded by the Ministry of Health & Welfare, Republic of Korea. J.M.S.: NIH (1P20RR021938-01). A.R.M.: NIH (P30GM122734, R01MH101512). C.M.D.-C.: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI17/00481, PI20/00721, JR19/00024). S. Cervenka: Swedish Research Council (523-2014-3467). M. Kirschner: Swiss National Science Foundation (SNSF) (P2SKP3_178175). T.H.: CIHR (142255), Ministry of Health of the Czech Republic (16-32791A, NU20-04-00393), Brain & Behavior Research Foundation (BBRF) Young and Independent Investigator Awards. A. James: Medical Research Council (MRC) (G0500092). P.H.: NARSAD grant from the BBRF (28445), Research Grant from the Novartis Foundation (20A058). R.C.G.: NIH (1R01MH117014, 1R01MH119219). N.J.: NIH (R01MH117601). S.E.M.: NHMRC (APP1172917). J.A.T.: NIH (R01MH1​21246). Dataset-Specific Funding Sources and Acknowledgments: AMC: Supported by grants from The Netherlands Organisation for Health Research and Development (ZonMw) (3160007, 91676084, 31160003, 31180002, 31000056, 2812412, 100001002, 100002034), the Dutch Research Council (NWO) (90461193, 40007080, 48004004, 40003330), the Amsterdam Brain Imaging Platform, Neuroscience Campus Amsterdam, and the Dutch Brain Foundation. Processing with FreeSurfer was performed on the Dutch e-Science Grid through BiG Grid project and COMMIT project “e-Biobanking with imaging for healthcare,” which are funded by the NWO. ASRB: Australian Schizophrenia Research Bank, supported by the NHMRC (Enabling Grant, 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation, and the Schizophrenia Research Institute. Chief Investigators for ASRB were S.V.C., P.T.M., B.J.M., U.S., R.J.S., V.J.C., F.A.H., C.P., Assen Jablensky. We thank C.M.L., the ASRB Manager, and acknowledge the help of Jason Bridge for ASRB database queries. CAMH: Datasets were collected and shared with support from the CAMH Foundation and the CIHR. CASSI (Cognitive and Affective Symptoms in Schizophrenia Intervention): Supported by the University of New South Wales School of Psychiatry, the NHMRC (568807), Neuroscience Research Australia, the Schizophrenia Research Institute utilizing infrastructure funding from NSW Ministry of Health, the Macquarie Group Foundation, and the ASRB (see above). CIAM (Cortical Inhibition and Attentional Modulation): The CIAM group (PI: F.M.H.) was supported by the University Research Committee, University of Cape Town; South African National Research Foundation (NRF); South African Medical Research Council (SA MRC). CLING (Clinical Neuroscience Goettingen): Sample data collection partially supported by the Deutsche Forschungsgemeinschaft (DFG) (GR1950/5-1 to O.G.). COBRE (Center for Biomedical Research Excellence): Supported by NIH (R01EB006841, P20GM103472, 5R01MH094524 to V.D.C. and J.A.T. R01AA021771 and P50AA022534 to J.M.S.), and the NSF (1539067). EdinburghEHRS: Funded by the MRC (G9226254, G9825423), the Dr. Mortimer and Theresa Sackler Foundation. EdinburghFunc: Funded by the MRC Clinical Training Fellowship (G84/5699) and Health Foundation Clinician Scientist Fellowship (2268/4295). EdinburghSFMH: Funded by an award from the Translational Medicine Research Collaboration (NS_EU_166), Scottish Enterprise, Pfizer, the Dr. Mortimer and Theresa Sackler Foundation. The University of Edinburgh is a charitable body, registered in Scotland, with registration number SC005336. Is e buidheann carthannais a th’ ann an Oilthigh Dhùn Èideann, clàraichte an Alba, àireamh clàraidh SC005336. EONCKS: Supported by the SA MRC and the New Partnership for Africa’s Development initiative through the Department of Science and Technology of South Africa (#65174). ESO: Supported by the Ministry of Health of the Czech Republic (NU20-04-00393). FBIRN (Function Biomedical Informatics Research Network): Supported by the National Center for Research Resources at the NIH (1 U24 RR021992 (FBIRN) and 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center; http://www.birncommunity.org)). Data were processed by the UCI High-Performance Computing cluster supported by Joseph Farran (supported by NIMH R01 MH-58262), Harry Mangalam, and Adam Brenner (supported by NIH 5R01 MH61603, 2R01MH058251), and the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH (through grant UL1 TR000153). FBIRN thank Mrs. Liv McMillan for overall study coordination. FOR2107 Marburg: Funded by the DFG, T.T.J.K. (speaker FOR2107; KI588/14-1, KI588/14-2), Axel Krug (KR3822/5-1, KR3822/7-2), I.N. (NE2254/1-2, NE2254/3-1, NE2254/4-1), Carsten Konrad (KO4291/3-1), and A. Jansen (JA1890/7-1, JA1890/7-2). FOR2107 Münster: Funded by the DFG (FOR2107 DA1151/5-1, DA1151/5-2 to U.D.; SFB-TRR58, Projects C09 and Z02 to U.D.) and the Interdisciplinary Center for Clinical Research of the medical faculty of Münster (Dan3/012/17 to U.D.). Frankfurt: MRI was performed at the Frankfurt Brain Imaging Centre, supported by the DFG and the German Ministry for Education and Research (Brain Imaging Center Frankfurt/Main, DLR01GO0203). GAP (Genetics and Psychosis): The GAP dataset represents independent research funded by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at South London, Maudsley National Health Service (NHS) Foundation Trust, and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. GIPSI: Supported by “PRISMA U.T” Colciencias Invitación 990 del 3 de Agosto de 2017, Código 111577757629, Contrato 781 de 2017. GROUP: We thank Truda Driesen and Inge Crolla for their coordinating roles in the data collection, as well as the G.R.O.U.P. investigators: R.S.K., Don H. Linszen, Jim van Os, Durk Wiersma, Richard Bruggeman, W.C., L.dH., Lydia Krabbendam, Inez Myin-Germeys. Infrastructure for the GROUP study is funded through the Geestkracht programme of ZonMw (10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord Holland Noord; Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia psycho-medical center, The Hague; Maastricht: Maastricht University Medical Centre and the mental health institutions: GGzE, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh voor Geestelijke Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem; Utrecht: University Medical Center Utrecht and the mental health institutions Altrecht, GGZ Centraal, and Delta). HMS (Homburg Multidiagnosis Study): Sample data collection was supported by a grant of the Competence Network Schizophrenia to O.G. HUBIN (Human Brain Informatics): Supported by the Swedish Research Council (K2015-62X-15077-12-3), 2017-00949, the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, the Knut and Alice Wallenberg Foundation. Huilong: Funded by the National Natural Science Foundation of China (81761128021; 31671145; 81401115; 81401133), Beijing Municipal Science & Technology Commission grant (Z141107002514016), Beijing Natural Science Foundation (7162087), Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding (XMLX201609; zylx201409). IGP: Imaging Genetics in Psychosis study, funded by Project Grants from the NHMRC (APP630471 and APP1081603), and the Macquarie University’s ARC Centre of Excellence in Cognition and its Disorders (CE110001021). This project used participants from the ASRB (see above), using an infrastructure grant from the NSW Ministry of Health. IMH: Supported by research grants from the National Healthcare Group, Singapore (SIG/05004; SIG/05028), and the Singapore Bioimaging Consortium (RP C009/2006) awarded to K.S. KaSP: Supported by the Swedish Research Council (K2015-62X-15077-12-3), and by grants from the Swedish Medical Research Council (2009-7053, 2013-2838, 523-2014-3467), the Swedish Brain Foundation, Åhlén-siftelsen, Svenska Läkaresällskapet, Petrus och Augusta Hedlunds Stiftelse, Torsten Söderbergs Stiftelse, the AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science, Söderbergs Königska Stiftelse, Professor Bror Gadelius Minne, Knut och Alice Wallenbergs stiftelse, the Swedish Federal Government under the LUA/ALF agreement (C.M.S., S. Cervenka), Centre for Psychiatry Research, KID-funding from the Karolinska Institutet. Madrid: Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), cofinanced by ERDF Funds from the European Commission, “A way of making Europe,” CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program (FP7-4-HEALTH-2009-2.2.1-2-241909—Project EU-GEI, FP7-HEALTH-2013-2.2.1-2-603196—Project PSYSCAN, and FP7-HEALTH-2013-2.2.1-2-602478—Project METSY), European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (115916—Project PRISM, and 777394—Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz. MCIC: Supported by the NIH (NIH/NCRR P41RR14075, R01EB005846 to V.D.C.), the Department of Energy (DE-FG02- 99ER62764), the Mind Research Network, the Morphometry BIRN (1U24, RR021382A), the Function BIRN (U24RR021992-01, NIH.NCRR MO1 RR025758-01, NIMH 1RC1MH089257 to V.D.C.), the DFG (research fellowship to S.E.), and a NARSAD Young Investigator Award (to S.E.). MPRC: Support received from NIH (U01MH108148, 2R01EB015611, R01MH112180, R01DA027680, R01MH085646, P50MH103222, and T32MH067533), a State of Maryland contract (M00B6400091), and NSF grant (1620457). OLIN: Supported by NIH (R01MH106324, R01MH077945). Osaka: Partially supported by AMED (JP21dm0307002, JP21dm0207069, JP21dk0307103, JP21uk1024002, and JP21wm0425012), JSPS KAKENHI (JP20H03611, JP20K06920), and Intramural Research Grant (3-1) for Neurological and Psychiatric Disorders of NCNP. Computations were performed using Research Center for Computational Science, Okazaki, Japan. Oxford: We would like to thank the participants and their families, referring psychiatrists, and the Donnington Health Centre, Oxford. This study is supported by the MRC, OHSRC, UK EPSRC, BBSRC, and Wellcome Trust. PAFIP: We wish to thank all PAFIP research teams and all patients and family members who participated in the study. PAFIP has been funded by Instituto de Salud Carlos III through the projects PI14/00639, PI14/00918, and PI17/01056 (cofunded by ERDF/ESF “Investing in your future”), Health Research Institute Marques de Valdecilla (NTC0235832, NCT02534363), Instituto de Salud Carlos III, FIS 00/3095, 01/3129, PI020499, PI060507, PI10/00183, the SENY Fundació Research Grant (CI 2005‐0308007), the Fundación Marqués de Valdecilla (API07/011), MINECOSAF2013-46292-R, PSYSCAN (Exp.: HEALTH.2013.2.2.1-2_Grant agreement no. 603196). We want to particularly acknowledge the patients and the BioBankValdecilla (PT13/0010/0024) integrated in the Spanish National Biobanks Network for its collaboration. We thank IDIVAL Neuroimaging Unit for its help in the technical execution of this work. RSCZ: Supported in part by the RFBR (20-013-00748). SCORE: This study was supported in part by the SNSF (3232BO_119382). We thank the FePsy (Frueherkennung von Psychosen; early detection of psychosis) Study Group from the University of Basel, Department of Psychiatry, Switzerland, for the recruitment of the study participants. The FePsy Study was supported in part by grant no. SNF 3200-057216/1, ext./2, ext./3. SNUH: Supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and the Korea Brain Research Institute (KBRI) basic research program through the KBRI, funded by the Ministry of Science, ICT & Future Planning (2019R1C1C1002457, 2020M3E5D9079910, 21-BR-03–01). SWIFT: Supported in part by the SNSF (320030_146789). TOP: Supported by the Research Council of Norway (#160181, 190311, 223273, 213837, 249711), the South-East Norway Health Authority (2014114, 2014097, 2017- 112), the Kristian Gerhard Jebsen Stiftelsen (SKGJ‐MED‐008), and the European Community’s Seventh Framework Programme (FP7/2007–2013), grant agreement no. 602450 (IMAGEMEND). UCISZ: Supported by the NIMH (R21MH097196 to T.G.M.v.E.). Data were processed by the UCI High-Performance Computing cluster (see FBIRN). UMCU: Supported by ZonMw (90802123, 91746370 to H.E.H.P., and 10-000-1001 to R.S.K.). UNIBA: Supported by grant funding from the Italian Ministry of Research (2017M7SZM8_004, PI A.B.; 2017K2NEF4, PI G.P.). UNIMAAS: Supported by ZonMw (91112002) and by a personal grant to T.v.A. (ZonMw-VIDI: 91712394). This clinical trial was registered in the Dutch clinical trial registry under ID: NTR5094 (https://trialsearch.who.int/Trial2.aspx?TrialID=NTR5094). Zurich: Funded by the SNSF., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Accelerated Cortical Thinning in Schizophrenia Is Associated With Rare and Common Predisposing Variation to Schizophrenia and Neurodevelopmental Disorders

  • González-Peñas, Javier
  • Alloza, Clara
  • Brouwer, Rachel
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • González-Lois, Noemí
  • Gallego, Ana Guil
  • Hoyos, Lucía de
  • Gurriarán, Xaquín
  • Andreu-Bernabeu, Álvaro
  • Romero-García, Rafael
  • Fañanás, Lourdes
  • Bobes, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Arrojo, Manuel
  • Vilella, Elisabet
  • Gutiérrez-Zotes, Alfonso
  • Perez-Rando, Marta
  • Moltó, María Dolores
  • Buimer, Elizabeth
  • van Haren, Neeltje
  • Cahn, Wiepke
  • O'Donovan, Michael
  • Kahn, René S
  • Arango, Celso
  • Pol, Hilleke Hulshoff
  • Janssen, Joost
  • Schnack, Hugo
Schizophrenia is a highly heritable disorder characterized by increased cortical thinning throughout the life span. Studies have reported a shared genetic basis between schizophrenia and cortical thickness. However, no genes whose expression is related to abnormal cortical thinning in schizophrenia have been identified., This work was supported by Spanish Ministry of Science, Innovation and Universities Instituto de Salud Carlos III (Grant Nos. SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, and PI20/00721), cofinanced by European Regional Development Funds from the European Commission, “A way of making Europe,” CIBERSAM (Centro de Investigación Biomédica en Red de Salud Menta); Madrid Regional Government (Grant No. B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; the European Union Seventh Framework Program (Grant Nos. FP7-4-HEALTH-2009-2.2.1-2-241909 [Project EU-GEI], FP7- HEALTH-2013-2.2.1-2-603196 [Project PSYSCAN], and FP7-HEALTH-2013-2.2.1-2-602478 [Project METSY]); and the European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (Grant No. 115916, Project PRISM, and Grant No. 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. CMD-C holds a Juan Rodés Grant from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (Grant No. JR19/00024). JG-P held a Sara Borrell grant during the development of the research from Instituto de Salud Carlos III (Grant No. CD20/00118)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs

  • Sønderby, Ida E.
  • Ching, Christopher R. K.
  • Thomopoulos, Sophia I.
  • Meer, Dennis van der
  • Sun, Daqiang
  • Villalón-Reina, Julio E.
  • Agartz, Ingrid
  • Amunts, Katrin
  • Arango, Celso
  • Armstrong, Nicola J.
  • Ayesa-Arriola, Rosa
  • Bakker, Geor
  • Bassett, Anne S.
  • Boomsma, Dorret I.
  • Bülow, Robin
  • Butcher, Nancy J.
  • Calhoun, Vince D.
  • Caspers, Svenja
  • Chow, Eva W C
  • Cichon, Sven
  • Ciufolini, Simone
  • Craig, Michael C.
  • Crespo-Facorro, Benedicto
  • Cunningham, Adam C.
  • Dale, Anders M.
  • Dazzan, Paola
  • de Zubicaray, Greig I.
  • Djurovic, Srdjan
  • Doherty, Joanne L.
  • Donohoe, Gary
  • Draganski, Bogdan
  • Durdle, Courtney A.
  • Ehrlich, Stefan
  • Emanuel, Beverly S.
  • Espeseth, Thomas
  • Fisher, Simon E.
  • Ge, Tian
  • Glahn, David C.
  • Grabe, Hans J.
  • Gur, Raquel E.
  • Gutman, Boris A.
  • Haavik, Jan
  • Håberg, Asta K.
  • Hansen, Laura A.
  • Hashimoto, Ryota
  • Hibar, Derrek P.
  • Holmes, Avram J.
  • Hottenga, Jouke-Jan
  • Hulshoff Pol, Hilleke E
  • Jalbrzikowski, Maria
  • Knowles, Emma E. M.
  • Kushan, Leila
  • Linden, David E J.
  • Liu, Jingyu
  • Lundervold, Astri J.
  • Martin-Brevet, Sandra
  • Martínez, Kenia
  • Mather, Karen A.
  • Mathias, Samuel R.
  • McDonald-McGinn, Donna M.
  • McRae, Allan F.
  • Medland, Sarah E.
  • Moberget, Torgeir
  • Modenato, Claudia
  • Monereo Sánchez, Jennifer
  • Moreau, Clara A.
  • Mühleisen, Thomas W.
  • Paus, Tomas
  • Pausova, Zdenka
  • Prieto, Carlos
  • Ragothaman, Anjanibhargavi
  • Reinbold, Céline S.
  • Reis Marques, Tiago
  • Repetto, Gabriela M.
  • Reymond, Alexandre
  • Roalf, David R.
  • Rodriguez-Herreros, Borja
  • Rucker, James J.
  • Sachdev, Perminder S.
  • Schmitt, James E.
  • Schofield, Peter R.
  • Silva, Ana I.
  • Stefansson, Hreinn
  • Stein, Dan J.
  • Tamnes, Christian K.
  • Tordesillas-Gutiérrez, Diana
  • Ulfarsson, Magnus O.
  • Vajdi, Ariana
  • van 't Ent, Dennis
  • Bree, Marianne B. M. van den
  • Vassos, Evangelos
  • Vázquez-Bourgon, Javier
  • Vila-Rodriguez, Fidel
  • Walters, G Bragi
  • Wen, Wei
  • Westlye, Lars T.
  • Wittfeld, Katharina
  • Zackai, Elaine H.
  • Stefánsson, Kári
  • Jacquemont, Sebastien
  • Thompson, Paul M.
  • Bearden, Carrie E.
  • Andreassen, Ole A.
  • ENIGMA-CNV Working Group
  • ENIGMA 22q11.2 Deletion Syndrome Additional
Data sharing is not applicable to this article as no new data were created or analyzed in this study., ENIGMA-CNV Additional Members: Manon Bernard, Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada. Nicholas B. Blackburn, Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Brownsville, Texas, USA; South Texas Diabetes and Obesity Institute, School of Medicine, University of Texas Rio Grande Valley, Brownsville, Texas, USA. Rune Bøen, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway; Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway. Eco de Geus, Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Amsterdam Public Health (APH) Research Institute, Amsterdam UMC, Amsterdam, The Netherlands. Sonja M. C. de Zwarte, Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Marta Di Forti, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Oleksandr Frei, Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health; Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway and Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway, Vincent Frouin, Université Paris-Saclay, CEA, Neurospin, Gif-sur-Yvette, France. Masaki Fukunaga, Division of Cerebral Integration, National Institute for Physiological Sciences, Okazaki, Japan. Jayne Y. Hehir-Kwa, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Manon H. J. Hillegers, Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Center, Rotterdam, The Netherlands. Per Hoffmann, Institute of Human Genetics, University of Bonn, Bonn, Germany; Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland. Georg Homuth, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. Neda Jahanshad, Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA. Sanne Koops, Department of Biomedical Sciences of Cells & Systems, Cognitive Neurosciences, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands. Kuldeep Kumar, Sainte Justine Research Center, University of Montreal, Montreal, QC, Canada. Masataka Kikuchi, Graduate School of Medicine, Osaka University, Osaka, Japan. Stephanie Le Hellard, NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. Costin Leu, Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK; Stanley Center for Psychiatric Research, Broad Institute of Harvard and M.I.T, Cambridge, MA, USA. Robin M Murray, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Terje Nærland, KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway; NevSom, Department of Rare Disorders, Oslo University Hospital, Oslo, Norway. Lars Nyberg, Integrative Medical Biology (IMB) Umeå University, Umeå, Sweden; Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. Roel A. Ophoff, Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, CA, USA; Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. G Bruce Pike, Radiology and Clinical Neurosciences, University of Calgary, Calgary, AB, Canada. Sigrid B. Sando, Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway. Jean Shin, The Hospital for Sick Children, Toronto, ON, Canada; Departments of Physiology and Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada. Elena Shumskaya, Donders Institute for Brain, Cognition, and Behavior, Nijmegen, The Netherlands. Sanjay M. Sisodiya, Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK; Chalfont Centre for Epilepsy, Chalfont-St-Peter, Bucks, UK. Vidar M. Steen, NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. Alexander Teumer, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany, Anne Uhlmann, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. Margaret J. Wright, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia, ENIGMA 22q11.2 Deletion Syndrome Additional Members: Kevin M. Antshel, Department of Psychology, Syracuse University, Syracuse, NY, USA. Linda E. Campbell, University of Newcastle, Newcastle, NSW, Australia. Nicolas A. Crossley, Department of Psychiatry, Pontificia Universidad Católica de Chile, Santiago, Chile. T. Blaine Crowley, Division of Human Genetics and 22q and You Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Eileen Daly, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. Ania M. Fiksinski, Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, ON, Canada; Dalglish Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, ON, Canada; Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Jennifer K. Forsyth, Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA. Wanda Fremont, Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA. Naomi J. Goodrich-Hunsaker, MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, Davis, CA, USA; Department of Neurology, University of Utah, Salt Lake City, UT, USA. Maria Gudbrandsen, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. Rachel K. Jonas, Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences and Psychology, University of California Los Angeles, Los Angeles, CA, USA. Wendy R. Kates, Department of Psychiatry and Behavioral Sciences, State University of New York at Upstate Medical University, Syracuse, NY, USA. Amy Lin, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA. Kathryn L. McCabe, Department of Psychiatry and Behavioral Sciences, State University of New York at Upstate Medical University, Syracuse, NY, USA; Department of Psychology, University of Newcastle, Newcastle, NSW, Australia. Hayley Moss, MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. Declan G. Murphy, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK; Behavioural Genetics Clinic, Adult Autism Service, Behavioural and Developmental Psychiatry Clinical Academic Group, South London and Maudsley NHS Foundation Trust, London, UK. Kieran C. Murphy, Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland. Michael J. Owen, MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. Kosha Ruparel, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Tony. J. Simon, MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, Davis, CA, USA. Therese van Amelsvoort, Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands. Jacob A. S. Vorstman, Department of Psychiatry, The Hospital for Sick Children, Toronto, ON, Canada., The Enhancing NeuroImaging Genetics through Meta-Analysis copy number variant (ENIGMA-CNV) and 22q11.2 Deletion Syndrome Working Groups (22q-ENIGMA WGs) were created to gain insight into the involvement of genetic factors in human brain development and related cognitive, psychiatric and behavioral manifestations. To that end, the ENIGMA-CNV WG has collated CNV and magnetic resonance imaging (MRI) data from ~49,000 individuals across 38 global research sites, yielding one of the largest studies to date on the effects of CNVs on brain structures in the general population. The 22q-ENIGMA WG includes 12 international research centers that assessed over 533 individuals with a confirmed 22q11.2 deletion syndrome, 40 with 22q11.2 duplications, and 333 typically developing controls, creating the largest-ever 22q11.2 CNV neuroimaging data set. In this review, we outline the ENIGMA infrastructure and procedures for multi-site analysis of CNVs and MRI data. So far, ENIGMA has identified effects of the 22q11.2, 16p11.2 distal, 15q11.2, and 1q21.1 distal CNVs on subcortical and cortical brain structures. Each CNV is associated with differences in cognitive, neurodevelopmental and neuropsychiatric traits, with characteristic patterns of brain structural abnormalities. Evidence of gene-dosage effects on distinct brain regions also emerged, providing further insight into genotype–phenotype relationships. Taken together, these results offer a more comprehensive picture of molecular mechanisms involved in typical and atypical brain development. This “genotype-first” approach also contributes to our understanding of the etiopathogenesis of brain disorders. Finally, we outline future directions to better understand effects of CNVs on brain structure and behavior., The ENIGMA Consortium is supported by the NIH Big Data to Knowledge (BD2K) program under consortium grant number U54 EB020403 (PI: Thompson). OAA is supported by the Research Council of Norway, South East Norway Health Authority, KG Jebsen Stiftelsen, EU H2020. C. A. has been funded by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241,909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603,196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602,478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative two Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz. R. A-A is funded by a Miguel Servet contract from the Carlos III Health Institute (CP18/00003). G. B. is supported by the Dutch Organization for Health Research and Development ZonMw (grants 91112002 & 91712394). A. S. B. is supported by the Dalglish Family Chair in 22q11.2 Deletion Syndrome, Canadian Institutes of Health Research (CIHR) grants MOP-79518, MOP-89066, MOP-97800 and MOP-111238, and NIMH grant number U01 MH101723–01(3/5). C. E. B. is also supported by the National Institute of Mental Health: RO1 MH085953, R01 MH100900 and 1U01MH119736. N. E. B. is granted the KNAW Academy Professor Award (PAH/6635). V. D. C. is supported by NIH R01 MH094524. S. C. is supported by the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 945539 (Human Brain Project SGA3); Helmholtz Initiative and Networking Fund. C. R. K. C. is supported by NIA T32AG058507. E. W. C. C. is supported by the Canadian Institutes of Health Research, Ontario Mental Health Foundation grant MOP-74631 and NIMH grant U01MH101723–01(3/5). S. Ci. has received funding from the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 945539 (Human Brain Project SGA3). M. C. C. is supported by the Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. N. A. C. is supported by Agencia Nacional de Investigación y Desarrollo (ANID Chile) PIA ACT192064. GId. Z. is supported by the NHMRC. J. L. D. and D. E. J. L. are supported by the Wellcome Trust. T. B. C. is supported by NICHD grant PO1-HD070454, NIH grant UO1-MH191719, and NIMH grant R01 MH087636-01A1. AMD is supported by U24DA041147. B. D. is supported by the Swiss National Science Foundation (NCCR Synapsy, project grant numbers 32003B_135679, 32003B_159780, 324730_192755 and CRSK-3_190185), the Leenaards Foundation and the Roger De Spoelberch Foundation. SE is supported by the NARSAD-Young Investigator Grant “Epigenetic Regulation of Intermediate Phenotypes in Schizophrenia”. B. E. S. is supported by the NIH (NIMH). D. C. G. is supported by NIH grant numbers MH078143, MH083824, AG058464. W. R. K. is supported by NIH/MH R0106824. R. E. G. is supported by NIH/NIMH grant numbers MH087626, MH119737. DMMcD-McG is supported by National Institutes of Mental Health (NIMH), grant numbers MH119737-02; MH191719; and MH087636-01A1. S. E. M. is supported by NHMRC grants APP1103623; APP1158127; APP1172917. TM is supported by Research Council of Norway - grant number 273345. D. G. M. is supported by the National Institute for Health Research Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and EU-AIMS (European Autism Interventions)/EU AIMS-2-TRIALS, a European Innovative Medicines Initiative Joint Undertaking under grant agreements 115300 and 777394. T. N. was supported by Stiftelsen KG Jebsen under grant number SKGJ-MED-021. R. A. O. is supported by NIMH R01 MH090553. S. Y. S. has been funded by the Canadain Institutes of Health Research. M. J. O. is supported by MRC Centre grant MR/L010305/1 and Wellcome Trust grant 100,202/Z/12/Z; Dr. Owen has received research support from Takeda. Z. P. is supported by CIHR, CFI, HSFC. B. G. P. is supported by CIHR FDN 143290 and CAIP Chair. G. M. R. is supported by Fondecyt-Chile #1171014 and ANID-Chile ACT192064. A. Re. was supported by a grant from the Swiss National Science Foundation (31003A_182632). DRR is supported by R01 MH120174 (PI: Roalf). This report represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London (to J. J. R). PSS is supported by NHMRC (Australia) program grant 1093083. J. E. S. is supported by NIH K01-ES026840. S. M. S. is supported by the Epilepsy Society. T. J. S. is supported by NIH grants R01MH107108, R01HD042794, and HDU54079125. I. E. S. is supported by South-Eastern Norway Regional Health Authority (#2020060), European Union's Horizon2020 Research and Innovation Programme (CoMorMent project; grant #847776) and the KG Jebsen Foundation (SKGJ-MED-021). V. M. S. is supported by Research Council of Norway (CoE funding scheme, grant number 223273). D. J. S. is supported by the SA MRC. C. K. T. is supported by Research Council of Norway (#230345, #288083, #223273) and South-Eastern Norway Regional Health Authority (#2019069, #2021070, #500189). D. T.-G. was supported by the Instituto de Salud Carlos III (PI14/00639 and PI14/00918) and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). Dvd. M. is supported by Research Council of Norway #276082. F. V. R. is supported by the Michael Smith Foundation for Health Research Scholar Award. deCODE genetics has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreements' no. 115008 (NEWMEDS) and no. 115300 (EUAIMS), of which resources are composed of EFPIA in-kind contribution and financial contribution from the European Union's Seventh Framework Programme (EU-FP7/2007–2013). L. T. W. is supported by Research Council of Norway, European Research Council. The IDIVAL neuroimage unit is supported by Instituto de Salud Carlos III PI020499, research funding SCIII-INT13/0014, MICINN research funding SAF2010-20840-C02-02, SAF2013-46292-R. The TOP/NORMENT study are supported by the Research Council of Norway (#223273). The GOBS study data collection was supported in part by the National Institutes of Health (NIH) grants: R01 MH078143, R01 MH078111, and R01 MH083824 with work conducted in part in facilities constructed under the support of NIH grant number C06 RR020547. The Sydney Memory and Ageing Study has been funded by three National Health & Medical Research Council (NHMRC) Program Grants (ID No. ID350833, ID568969, and APP1093083). We thank the participants and their informants for their time and generosity in contributing to this research. We also acknowledge the MAS research team: https://cheba.unsw.edu.au/research-projects/sydney-memory-and-ageing-study. We acknowledge the contribution of the OATS research team (https://cheba.unsw.edu.au/project/older-australian-twins-study) to this study. The OATS study has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Aging Well, Aging Productively Program (ID No. 401162); NHMRC Project (seed) Grants (ID No. 1024224 and 1025243); NHMRC Project Grants (ID No. 1045325 and 1085606); and NHMRC Program Grants (ID No. 568969 and 1093083). We thank the participants for their time and generosity in contributing to this research. This research was facilitated through access to Twins Research Australia, a national resource supported by a Centre of Research Excellence Grant (ID No. 1079102) from the National Health and Medical Research Council. The NCNG sample collection was supported by grants from the Bergen Research Foundation and the University of Bergen, the Dr Einar Martens Fund, the KG Jebsen Foundation, the Research Council of Norway, to S. L. H., V. M. S., A. J. L., and T. E. The authors thank Dr. Eike Wehling for recruiting participants in Bergen, and Professor Jonn-Terje Geitung and Haraldplass Deaconess Hospital for access to the MRI facility. Additional support by RCN grants 177458/V50 and 231286/F20. The Betula study was supported by a Wallenberg Scholar Grant (KAW). The HUNT Study is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU—Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, and the Norwegian National Advisory Unit for functional MRI. Research for the GAP cohort was supported by the Department of Health via the National Institute for Health Research (NIHR) Specialist Biomedical Research Center for Mental Health award to South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry at King's College London, London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. S.J. is supported by Calcul Quebec (http://www.calculquebec.ca), Compute Canada (http://www.computecanada.ca), the Brain Canada Multi investigator research initiative (MIRI), the Institute of Data Valorization (Canada First Research Excellence Fund), CHIR, Canada Research Chairs and the Jeanne et Jean Louis Levesque Foundation. The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO), MW904-61-193 (de Geus & Boomsma), MaGWnr: 400-07-080 (van 't Ent), MagW 480-04-004 (Boomsma), NWO/SPI 56-464-14,192 (Boomsma), the European Research Council, ERC-230374 (Boomsma), and Amsterdam Neuroscience. Funding for genotyping was obtained from the National Institutes of Health (NIMH U24 MH068457-06; Grand Opportunity grants 1RC2 MH089951, and 1RC2 MH089995); the Avera Institute for Human Genetics, Sioux Falls, South Dakota (USA). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. The Brainscale study was supported by the Netherlands Organization for Scientific Research MagW 480-04-004 (Boomsma), 51.02.060 (Hilleke Hulshoff Pol), 668.772 (Boomsma & Hulshoff Pol); NWO/SPI 56-464-14192 (Boomsma), the European Research Council (ERC230374) (Boomsma), High Potential Grant Utrecht University (Hulshoff Pol), NWO Brain and Cognition 433-09-220 (Hulshoff Pol). SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide SNP typing in SHIP and MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The ENIGMA-22q11.2 Deletion Syndrome Working Group wishes to acknowledge our dear colleague Dr. Clodagh Murphy, who sadly passed away in April 2020. Open access funding enabled and organized by Projekt DEAL., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Social brain, social dysfunction and social withdrawal

  • Porcelli, S.
  • Van Der Wee, N.
  • van der Werff, S.
  • Aghajani, M.
  • Glennon, J.C.
  • van Heukelum, S.
  • Mogavero, F.
  • Lobo, A.
  • Olivera, F.J.
  • Lobo, E.
  • Posadas, M.
  • Dukart, J.
  • Kozak, R.
  • Arce, E.
  • Ikram, A.
  • Vorstman, J.
  • Bilderbeck, A.
  • Saris, I.
  • Kas, M.J.
  • Serretti, A.
The human social brain is complex. Current knowledge fails to define the neurobiological processes underlying social behaviour involving the (patho-) physiological mechanisms that link system-level phenomena to the multiple hierarchies of brain function. Unfortunately, such a high complexity may also be associated with a high susceptibility to several pathogenic interventions. Consistently, social deficits sometimes represent the first signs of a number of neuropsychiatric disorders including schizophrenia (SCZ), Alzheimer''s disease (AD) and major depressive disorder (MDD) which leads to a progressive social dysfunction. In the present review we summarize present knowledge linking neurobiological substrates sustaining social functioning, social dysfunction and social withdrawal in major psychiatric disorders. Interestingly, AD, SCZ, and MDD affect the social brain in similar ways. Thus, social dysfunction and its most evident clinical expression (i.e., social withdrawal) may represent an innovative transdiagnostic domain, with the potential of being an independent entity in terms of biological roots, with the perspective of targeted interventions.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection

  • Gilmour, G.
  • Porcelli, S.
  • Bertaina-Anglade, V.
  • Arce, E.
  • Dukart, J.
  • Hayen, A.
  • Lobo, A.
  • Lopez-Anton, R.
  • Merlo Pich, E.
  • Pemberton, D.J.
  • Havenith, M.N.
  • Glennon, J.C.
  • Harel, B.T.
  • Dawson, G.
  • Marston, H.
  • Kozak, R.
  • Serretti, A.
Central nervous system diseases are not currently diagnosed based on knowledge of biological mechanisms underlying their symptoms. Greater understanding may be offered through an agnostic approach to traditional disease categories, where learning more about shared biological mechanisms across conditions could potentially reclassify sub-groups of patients to allow realisation of more effective treatments. This review represents the output of the collaborative group “PRISM”, tasked with considering assay choices for assessment of attention and working memory in a transdiagnostic cohort of Alzheimer''s disease and schizophrenia patients exhibiting symptomatic spectra of social withdrawal. A multidimensional analysis of this nature has not been previously attempted. Nominated assays (continuous performance test III, attention network test, digit symbol substitution, N-back, complex span, spatial navigation in a virtual environment) reflected a necessary compromise between the need for broad assessment of the neuropsychological constructs in question with several pragmatic criteria: patient burden, compatibility with neurophysiologic measures and availability of preclinical homologues.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Pgc1a is responsible for the sex differences in hepatic Cidec/Fsp27ß mRNA expression in hepatic steatosis of mice fed a western diet

  • Herrera-Marcos, Luis V.
  • Sancho-Knapik, Sara
  • Gabás-Rivera, Clara
  • Barranquero, Cristina
  • Gascón, Sonia
  • Romanos, Eduardo
  • Martínez-Beamonte, Roberto
  • Navarro, María A.
  • Surra, Joaquín C.
  • Arnal, Carmen
  • García-de-Jalón, José A.
  • Rodríguez-Yoldi, María J.
  • Tena-Sempere, Manuel
  • Sánchez-Ramos, Cristina
  • Monsalve, María
  • Osada, Jesús
Hepatic fat-specific protein 27 (Cidec/Fsp27) mRNA levels have been associated with hepatic lipid droplet extent under certain circumstances. To address its hepatic expression under different dietary conditions and in both sexes, Apoe-deficient mice were subjected to different experimental conditions for 11 weeks to test the influence of cholesterol, Western diet, squalene, oleanolic acid, sex and surgical castration on Cidec/Fsp27 mRNA expression. Dietary cholesterol increased hepatic Cidec/Fsp27ß expression, an effect that was suppressed when cholesterol was combined with saturated fat as represented by Western-diet feeding. Using the latter diet, oleanolic acid or squalene did not modify its expression. Females showed lower levels of hepatic Cidec/Fsp27ß expression than males when they were fed Western diets, a result that was translated into lesser amount of CIDEC/FSP27 protein in lipid droplets and microsomes. This was also confirmed in Ldlr-deficient mice. Incubation with estradiol resulted in decreased Cidec/Fsp27ß expression in AML12 cells. While male surgical castration did not modify the expression, ovariectomized females did show increased levels compared to control females. Females also showed increased expression of Pgc1a, suppressed by ovariectomy, and the values were significantly and inversely associated with those of Cidec/Fsp27ß. When Pgc1a-deficient mice were used, the sex differences on Cidec/Fsp27ß expression disappeared. Therefore, hepatic Cidec/Fsp27ß expression has a complex regulation influenced by diet and sex hormonal milieu. The mRNA sex differences are controlled by Pgc1a.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, Aleix
  • Mezquida, Gisela
  • Janssen, Joost
  • Amoretti, Silvia
  • Lobo, Antonio
  • González-Pinto, Ana
  • Arango, Celso
  • Vieta, Eduard
  • Castro-Fornieles, Josefina
  • Bergé, Daniel
  • Albacete, Auria
  • Giné, Eloi
  • Parellada, Mara
  • Bernardo, Miguel
  • Bioque, Miquel
  • Morén, Constanza
  • Pina-Camacho, Laura
  • Díaz-Caneja, Covadonga M.
  • Zorrilla, Iñaki
  • Corres, Edurne Garcia
  • De-La-Camara, Concepción
  • Barcones, Fe
  • Escarti, María José
  • Aguilar, Eduardo Jesus
  • Legido, Teresa
  • Martin, Marta
  • Verdolini, Norma
  • Martinez-Aran, Anabel
  • Baeza, Immaculada
  • de la Serna, Elena
  • Contreras, Fernando
  • Bobes, Julio
  • García-Portilla, María Paz
  • Sanchez-Pastor, Luis
  • Rodriguez-Jimenez, Roberto
  • Usall, Judith
  • Butjosa, Anna
  • Salgado-Pineda, Pilar
  • Salvador, Raymond
  • Pomarol-Clotet, Edith
  • Radua, Joaquim
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18–24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Cortical thinning over two years after first-episode psychosis depends on age of onset

  • Pina-Camacho, Laura
  • Martinez, Kenia
  • Diaz-Caneja, Covadonga M.
  • Mezquida, Gisela
  • Cuesta, Manuel J.
  • Moreno, Carmen
  • Amoretti, Silvia
  • González-Pinto, Ana
  • Arango, Celso
  • Vieta, Eduard
  • Castro-Fornieles, Josefina
  • Lobo, Antonio
  • Fraguas, David
  • Bernardo, Miguel
  • Janssen, Joost
  • Parellada, Mara
  • Madero, Santiago
  • Gómez-Ramiro, Marta
  • Rodriguez-Toscano, Elisa
  • Santonja, Javier
  • Zorrilla, Iñaki
  • González-Ortega, Itxaso
  • Fayed, Nicolás
  • Santabárbara, Javier
  • Berge, Daniel
  • Toll, Alba
  • Nacher, Juan
  • García Martí, Gracián
  • Sague-Vilavella, Maria
  • Sanchez-Moreno, Jose
  • de la Serna, Elena
  • Baeza, Immaculada
  • Saiz-Masvidal, Cristina
  • Contreras, Fernando
  • González-Blanco, Leticia
  • Bobes-Bascarán, Teresa
  • Dompablo, Mónica
  • Rodriguez-Jimenez, Roberto
  • Usall, Judith
  • Butjosa, Anna
  • Pomarol-Clotet, Edith
  • Sarró, Salvador
First-episode psychosis (FEP) patients show structural brain abnormalities at the first episode. Whether the cortical changes that follow a FEP are progressive and whether age at onset modulates these changes remains unclear. This is a multicenter MRI study in a deeply phenotyped sample of 74 FEP patients with a wide age range at onset (15–35 years) and 64 neurotypical healthy controls (HC). All participants underwent two MRI scans with a 2-year follow-up interval. We computed the longitudinal percentage of change (PC) for cortical thickness (CT), surface area (CSA) and volume (CV) for frontal, temporal, parietal and occipital lobes. We used general linear models to assess group differences in PC as a function of age at FEP. We conducted post-hoc analyses for metrics where PC differed as a function of age at onset. We found a significant age-by-diagnosis interaction effect for PC of temporal lobe CT (d = 0.54; p = 002). In a post-hoc-analysis, adolescent-onset (≤19 y) FEP showed more severe longitudinal cortical thinning in the temporal lobe than adolescent HC. We did not find this difference in adult-onset FEP compared to adult HC. Our study suggests that, in individuals with psychosis, CT changes that follow the FEP are dependent on the age at first episode, with those with an earlier onset showing more pronounced cortical thinning in the temporal lobe.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

La psiquiatría post-COVID-19

  • Vieta, Eduard
  • Pérez Solà, Víctor
  • Arango, Celso
EV would like to thank the Ministry of Science and Research (PI15/00283, PI18/00805) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), the Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 1365), and project SLT006/17/00357 of the Strategic Plan for Health Research and Innovation (PERIS) 2016–2020 (Department of Health), CERCA PROGRAM, Government of Catalonia. VP would like to thank the Ministry of Science and Research (PI19/00236) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), CIBERSAM G21. Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 134), CERCA Program, Government of Catalonia. CA has received support from the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by the European Commission's ERDF Fund, “A way of making Europe,” CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No. 115916, Project PRISM, and grant agreement No. 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, and Fundación Alicia Koplowitz.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • De Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás Saura, Lourdes
  • Bobes García, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, M. Dolors
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango López, Celso
  • González-Peñas, Javier
Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N = 3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis

  • Molina García, Mariola
  • Fraguas, David
  • Del Rey Mejias, Angel
  • Mezquida Mateos, Gisela
  • Sánchez-Torres, Ana M.
  • Amoretti Guadall, Silvia
  • Lobo, Antonio
  • González-Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta i Pascual, Eduard, 1963-
  • Baeza, Inmaculada, 1970-
  • Mané Santacana, Anna
  • Cuesta, Manuel J.
  • Serna Gómez, Elena de la
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo Arroyo, Miquel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, Aleix|||0000-0002-2491-200X
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Janssen, Joost|||0000-0001-7613-2067
  • Amoretti, Silvia|||0000-0001-6017-2734
  • Lobo, Antonio|||0000-0002-9098-655X
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Arango, Celso|||0000-0003-3382-4754
  • Vieta, Eduard|||0000-0002-0548-0053
  • Castro-Fornieles, Josefina|||0000-0003-0632-2687
  • Bergé Baquero, Daniel|||0000-0003-2544-1016
  • Albacete, Auria|||0000-0003-4156-4972
  • Giné Serven, Eloi|||0000-0002-3130-5566
  • Parellada, Mara|||0000-0001-7977-3601
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Radua, Joaquim|||0000-0003-1240-5438
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18-24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study

  • Pignon, B.
  • Peyre, H.
  • Ayrolles, A.
  • Bobes, Julio|||0000-0003-2187-4033
the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI) and FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS) (...), Pignon B, Peyre H, Ayrolles A, Kirkbride JB, Jamain S, Ferchiou A, Richard JR, Baudin G, Tosato S, Jongsma H, de Haan L, Tarricone I, Bernardo M, Velthorst E, Braca M, Arango C, Arrojo M, Bobes J, Del-Ben CM, Di Forti M, Gayer-Anderson C, Jones PB, La Cascia C, Lasalvia A, Menezes PR, Quattrone D, Sanjuán J, Selten JP, Tortelli A, Llorca PM, van Os J, Rutten BPF, Murray RM, Morgan C, Leboyer M, Szöke A, Schürhoff F
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, A.
  • Mezquida, G.
  • Janssen, J.
  • Amoretti, S.
  • Bobes, Julio|||0000-0003-2187-4033
  • García-Portilla González, María Paz|||0000-0003-3643-1622
  • PEPs Group
We are grateful to all participants. We would also like to thank the Instituto de Salud Carlos III, the Spanish Ministry of Science, Innovation, and Universities, the European Regional Development Fund (ERDF/FEDER), European Social Fund, “Investing in your future”, “A way of making Europe” (projects: PI08/0208, PI11/00325, PI14/00292, PI14/ 00612, PI14/01148, PI14/01151, PI17/00481, PI17/01997, PI18/01055, PI19/00394, PI19/00766, PI20/00721, PI20/01342, and PI21/00713; contracts: CP14/00041, JR19/ 00024, CPII19/00009, and CD20/00177); CERCA Program; Catalan Government, the Secretariat of Universities and Research of the Department of Enterprise and Knowledge (2017SGR01271, 2017SGR1355, and 2017SGR1365); Institut de Neurociències, Universitat de Barcelona; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2); the University of the Basque Country (2019 321218ELCY GIC18/107); the Basque Government (2017111104); European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS) (...), Solanes A, Mezquida G, Janssen J, Amoretti S, Lobo A, González-Pinto A, Arango C, Vieta E, Castro-Fornieles J, Bergé D, Albacete A, Giné E, Parellada M, Bernardo M; PEPs group (collaborators); Pomarol-Clotet E, Radua J
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study

  • Trotta, Giulia
  • Rodríguez, Victoria
  • Quattrone, Diego
  • Bobes, Julio|||0000-0003-2187-4033
  • EU-GEI WP2
The research leading to these results has received funding from the European Community's Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). C. A. was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS)..., Trotta, G; Rodriguez, V; Quattrone, D; Spinazzola, E; Tripoli, G; Gayer-Anderson, C; Freeman, TP; Jongsma, HE; Sideli, L; Aas, M; Stilo, SA; La Cascia, C; Ferraro, L; La Barbera, D; Lasalvia, A; Tosato, S; Tarricone, I; D'Andrea, G; Tortelli, A; Schürhoff, F; Szöke, A; Pignon, B; Selten, JP; Velthorst, E; de Haan, L; Llorca, PM; Menezes, PR; Del Ben, CM; Santos, JL; Arrojo, M; Bobes, J; Sanjuán, J; Bernardo, M; Arango, C; Kirkbride, JB; Jones, PB; Richards, A; Rutten, BP; Van Os, J; Austin-Zimmerman, I; Li, ZK; Morgan, C; Sham, PC; Vassos, E; Wong, C; Bentall, R; Fisher, HL; Murray, RM; Alameda, L; Di Forti, M Trotta, Giulia; Rodriguez, Victoria; Quattrone, Diego; Spinazzola, Edoardo; Tripoli, Giada; Gayer- Anderson, Charlotte; Freeman, Tom P.; Jongsma, Hannah E.; Sideli, Lucia; Aas, Monica; Stilo, Simona A.; La Cascia, Caterina; Ferraro, Laura; La Barbera, Daniele; Lasalvia, Antonio; Tosato, Sarah; Tarricone, Ilaria; D'Andrea, Giuseppe; Tortelli, Andrea; Schuerhoff, Franck; Szoeke, Andrei; Pignon, Baptiste; Selten, Jean-Paul; Velthorst, Eva; de Haan, Lieuwe; Llorca, Pierre-Michel; Rossi Menezes, Paulo; Del Ben, Cristina M.; Luis Santos, Jose; Arrojo, Manuel; Bobes, Julio; Sanjuan, Julio; Bernardo, Miquel; Arango, Celso; Kirkbride, James B.; Jones, Peter B.; Richards, Alexander; Rutten, Bart P.; Van Os, Jim; Austin- Zimmerman, Isabelle; Li, Zhikun; Morgan, Craig; Sham, Pak C.; Vassos, Evangelos; Wong, Chloe; Bentall, Richard; Fisher, Helen L.; Murray, Robin M.; Alameda, Luis; Di Forti, Marta, EU GEI WP2 Group
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Recent natural selection conferred protection against schizophrenia by non-antagonistic pleiotropy

  • González Peñas, J.
  • Hoyos, Lucía de
  • Díaz Caneja, C. M.
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. J González-Peñas holds a Sara Borrel from Instituto de Salud Carlos III (CD20/00118). C. M. Díaz-Caneja holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024)
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu Bernabeu, Á.
  • Díaz Caneja, C. M.
  • Costas, J.
  • De Hoyos, L.
  • Stella, C.
  • Gurriarán, X.
  • Alloza, C.
  • Fañanás, L.
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN), and FP7- HEALTH-2013-2.2.1-2- 602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. We are grateful to Paloma Pantoja for her assistance in the design of the figures. A.A.-B. holds a Rio Hortega Grant from Instituto de Salud Carlos III (CM20/00114). C.M.D.-C. holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024)., Andreu-Bernabeu, Á., Díaz-Caneja, C.M., Costas, J., De Hoyos, L., Stella, C., Gurriarán, X., Alloza, C., Fañanás, L., Bobes, J., González-Pinto, A., Crespo-Facorro, B., Martorell, L., Vilella, E., Muntané, G., Nacher, J., Molto, M.D., Aguilar, E.J., Parellada, M., Arango, C., González-Peñas, J.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations

  • Liu, D.
  • Meyer, D.
  • Fennessy, B.
  • Bobes, Julio|||0000-0003-2187-4033
European Union Horizon 2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement number 115916 (Project PRISM) and grant agreement number 777394 (Project AIMS-2-TRIALS)), Fundación Familia Alonso and Fundación Alicia Koplowitz. We acknowledge the Biobanc of Parc Sanitari Sant Joan de Déu and Centro de Investigación Biomédica en Red de Salud Mental for samples and data procurement. J.G.-P. holds a Sara Borrell grant from Instituto de Salud Carlos III (CD20/00118). B.R. has received support from the Spanish Ministry of Science and Innovation Instituto de Salud Carlos III (PI18/00213 and Miguel Servet grants CPII21/00008 and MS16/00153), cofinanced by European Regional Development Fund Funds from the European Commission (...), Liu D, Meyer D, Fennessy B, Feng C, Cheng E, Johnson JS, Park YJ, Rieder MK, Ascolillo S, de Pins A, Dobbyn A, Lebovitch D, Moya E, Nguyen TH, Wilkins L, Hassan A; Psychiatric Genomics Consortium Phase 3 Targeted Sequencing of Schizophrenia Study Team; Burdick KE, Buxbaum JD, Domenici E, Frangou S, Hartmann AM, Laurent-Levinson C, Malhotra D, Pato CN, Pato MT, Ressler K, Roussos P, Rujescu D, Arango C, Bertolino A, Blasi G, Bocchio-Chiavetto L, Campion D, Carr V, Fullerton JM, Gennarelli M, González-Peñas J, Levinson DF, Mowry B, Nimgaokar VL, Pergola G, Rampino A, Cervilla JA, Rivera M, Schwab SG, Wildenauer DB, Daly M, Neale B, Singh T, O'Donovan MC, Owen MJ, Walters JT, Ayub M, Malhotra AK, Lencz T, Sullivan PF, Sklar P, Stahl EA, Huckins LM, Charney AW
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The role of premorbid IQ and age of onset as useful predictors of clinical, functional outcomes, and recovery of individuals with a first episode of psychosis

  • Molina-García, Mariola
  • Fraguas, David
  • Rey-Mejías, Ángel del
  • Mezquida, Gisela
  • Sánchez Torres, Ana María
  • Amoretti, Silvia
  • Lobo, Antonio
  • González Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta, Eduard
  • Baeza, Inmaculada
  • Mané, Anna
  • Cuesta, Manuel J.
  • Serna, Elena de la
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo, Miguel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III, PI02/1248, PI03032, PI05/0678, PI08/0208 PI09/01442, PI11/00325, PI12/1303, PI14/00612, PI15/00723, PI17/009977, PI18/00753 cofinanced by ERDF Funds from the European Commission, 'A way of making Europe', CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2). The CERCA Program/Generalitat de Catalunya And Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l'any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345. European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTi-MISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña.